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ABSTRACT 
 
Changes to a cell's DNA can result in cancer, which is permanently sustained 
cellular proliferation. When malfunctioning genes, oncogenes, were verified to be 
of human origin in the 1970s, drugs were designed to target their encoded, 
abnormal enzymes. Tyrosine kinases have been established as an oft-modified 
oncogene enzyme family, but the protein tyrosine phosphatases (PTPs) were not 
investigated as thoroughly. PTPs have gradually been established as relevant 
enzymes that work in tandem with tyrosine kinases in cell signaling and are not 
just “house-keeping” enzymes. Some PTPs are thought to initiate tumorigenesis, 
and others may play a complementary role after the onset of cancer by extending 
the duration of cellular signals. Reversible inhibition of these enzymes by an 
oxalylamino group substituted on an ortho-carboxy aryl have been described in 
the literature. Modification of the oxalylamino group to favor irreversible 
inhibition of these cysteine-dependent enzymes may prevent inhibitor efflux by 
cells and subsequent mutation to gain resistance. Replacement of the oxalylamino 
group with halogenated propanoate and propenoate esters minimally inhibited 
cancer cell growth but did not inhibit activity of PTPs. Of the ortho-carboxy aryl 
structures, a methyl dichloropropanoate (compound 24) and a lactone alkene 
(compound 29) inhibited cell growth by 50% (GI-50) at micromolar 
concentrations. The GI-50s for compounds 24 and 29 were 19.9 (DU-145, 
prostate carcinoma) and 9.4 micromolar (A549, lung cancer), respectively. In 
contrast, brominated nitro lactones were able to inhibit both cancer cell growth 
and the activity of PTPs. In a sulforhodamine B assay, these compounds were 
ii 
able to achieve GI-50s as low 5.3 micromolar (compound 33 against BXPC-3, 
pancreatic adenocarcinoma), and some killed 50% of cancer cells (LC-50) at 
micromolar concentrations. Compound 33 displayed LC-50 of 23.3 micromolar 
(BXPC-3), and compound 35 had LC-50s of 32.9 and 32.7 micromolar against 
BXPC-3 and colon adenocarcinoma (KM20L2), respectively. A single 
concentration (100 micromolar) inhibition assay of inhibitor PTPs resulted in no 
enzyme activity for 4 out of 5 PTPs tested with compound 33. Similar results 
were obtained for compounds 35 and 37. Future analysis will determine if these 
bromo nitro lactones are irreversibly inhibiting PTPs. 
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1 INTRODUCTION 
1.1 Cancer and Proteins as Targets 
 Cancer is one of the leading causes of death in America. More than 1.6 
million new cases of cancer are expected to be reported in 2012. As many as 
577,000 people are expected to die from cancer in 2012.
1
 Cancer is caused by 
changes in DNA that result in development of abnormal cells. The abnormal cells 
usually arise from the expression of oncogenes, inactivation of a tumor-
suppressing gene or microRNA genes becoming abnormal.
2
 In general, cancer 
cells are permanently sustained (do not undergo apoptosis), they are able to grow 
despite contacting other cells (ignore “contact inhibition”) and they are capable of 
spreading to new, non-native tissues (metastasis). 
 The most aggressive cancers afflicted patients with a recognizable 
phenotype of excessive and abnormal tissue growth, which was treated by 
radiotherapy and surgery, and later, drugs. Treating cancer patients with drugs 
was generally not accepted among the medical community in the early to mid 
1900s. However, lethal sulfur mustard gases used in World War I were studied as 
potential drug leads during WWII. Those studies led to nitrogen mustard drugs 
being used as some of the earliest candidates for clinical investigations. These 
compounds are effective DNA alkylators that become reactive after an 
intramolecular displacement of a halogen atom by the nitrogen (Scheme 1). The 
resulting product is very electrophilic at the ring carbons. After alkylation of 
DNA, another ring can form to react with DNA a second time. 
 
2 
Scheme 1. Nitrogen mustard, “mustine” 
 
 
 Initially, mustards were used on late-stage cancer patients who no longer 
showed a positive response to radiotherapy.
3
 Unfortunately, providing a safe 
dosage to limit the cytotoxicity of these drugs was difficult, and most symptoms 
returned after promising remission. However, nitrogen mustards like chlorambucil 
and phosphoramide were developed despite these initial failures. These drugs 
have unsafe side-effects (e.g., mutations and cancerous development), but they are 
still used in the clinic. 
 By the 1960s and 1970s, tumor viruses were being thoroughly investigated 
as the potential origin of cancer cells. Studies of the Rous sarcoma virus (RSV), 
which is an avian RNA tumor virus, identified a viral gene, later termed v-src, 
that appeared to cause cancer.
4
 A homologue of v-src, called c-src, was later 
found within non-cancerous cells, however. This proto-oncogene, c-src, was 
recognized as originating within the cellular genetic code,
5
 and it can turn normal 
cells into cancerous ones when mutated or overexpressed. Tumor viruses 
themselves were determined to be responsible for eliciting this cancerous activity, 
but they were not the origin of cancerous genes.  
 Src was later discovered to be a tyrosine kinase,
6
 and inhibitors targeted 
toward many tyrosine kinases have since been developed.
7
 In contrast to RNA 
tumor viruses, certain defective cellular proteins like p53 were arising from DNA 
3 
tumor viruses.
8
 The p53 protein is a transcription factor that controls apoptosis, 
DNA repair and other important cellular functions. DNA tumor viruses were 
discovered to be affecting p53, resulting in a mutant, malfunctioning p53 protein. 
Thus, tumor suppressing genes like p53, sometimes called anti-oncogenes, cause 
cancer or allow it to proliferate when they are defective. Thus, inhibitors that 
target proteins need to selectively inhibit those that are responsible for 
tumorigenesis or proliferation. 
1.2 Enzyme Inhibition 
Enzyme inhibition by synthetic drugs can occur in many fashions. When 
the active site of an enzyme is targeted, the inhibitors are considered competitive 
since they will compete with the enzyme’s natural substrate. If the enzyme 
substrate is known, it is also investigated to determine any favorable interactions 
that can be utilized. If inhibition targets an allosteric site that causes a structural 
change in the enzyme, then it is considered a noncompetitive inhibitor. Inhibitors 
that block the catalytic pocket can greatly reduce the enzyme activity, but they 
must compete with the natural substrate, which may have very high affinity for 
the enzyme. Noncompetitive inhibitors can reduce enzyme activity at a constant 
rate regardless of the concentration of substrate present. 
Inhibitors need to bind to their target enzyme regardless of their type of 
inhibition. Designs attempt to facilitate an appropriate interaction that will lead to 
a molecule that is able to displace a natural substrate or effectively/permanently 
bind the target. Reversible inhibitors or slow-binding reversible inhibitors interact 
4 
with enzyme residues without permanently disabling it. This type of inhibition is 
desirable for cases when continuous treatment is necessary or if highly selective 
drugs cannot be developed to inhibit deleterious enzymes. Extended treatment can 
be undertaken that leads to growth of cancer cells being inhibited enough to 
reduce the tumor to an operable size or eliminate the cancer altogether. 
Irreversible inhibitors permanently bind enzymes to disable them. In these cases, 
the selectivity of a drug needs to be specific for a cancerous target. Even extended 
treatment with irreversible inhibitors that are selective is not ideal since they are 
likely to affect the same enzyme of normal cells too. 
Targeting a unique feature of enzymes can help lead to selective drugs. 
Factoring in the environment that a drug should bind to will help in developing 
inhibitors with advantageous interactions. For enzymes, targeting the catalytic 
residue or unique residues within the binding pocket is one method utilized. 
Cysteine is generally a neutral amino acid, but ionization of the sulfhydryl group 
can increase in proteins.
9
 When inside an enzyme binding pocket, the thiol can be 
deprotonated more readily, especially when basic amino acids are nearby, to 
become a good nucleophile. Cysteine’s reactivity was recently utilized in the 
development of an HER-2 inhibitor, neratinib or HKI-272.
10
 HER-2 is a tyrosine 
kinase that has a cysteine in the active-site. Even though it is not the catalytic 
residue, the authors hypothesized that it could still be targeted as a nucleophilic 
group. Neratinib is a Michael-acceptor that binds irreversibly to HER-2 and has 
progressed to several phase III clinical trials. A family of enzymes that work with 
tyrosine kinases in cell signaling are the tyrosine phosphatases. Similarly to HER-
5 
2, there is a cysteine in the enzyme-binding pocket, but it is the catalytic residue 
for almost all of the enzymes of this family. 
1.3 Relationship of Protein Tyrosine Phosphatases to Cancer and Other Diseases 
 The first tyrosine phosphatase to be discovered, PTP1B, was not isolated 
until ~ 10 years after the first tyrosine kinase.
11, 12
 Thus extensive investigation 
was slow to arise in comparison to PTKs. However, PTP1B was found to be 
valuable in regulating metabolism and as a potential target for treating type II 
diabetes.
13
 After this discovery and subsequent investigations, PTPs were given 
more attention for their roles in other diseases and cancer. 
There are at least 107 recognized protein tyrosine phosphatases (PTPs) in 
the human genome, and they are grouped into 4 Classes.
14
 Almost all PTPs are 
defined by a specific catalytic domain of the form (H/V)C(X)5R(S/T).
15
 
Depending on the source, the description of the catalytic pocket varies from the 
simple HCX5R
16
 to the more encompassing [I/V]HCxAGxxR[S/T]G.
17
 The latter 
description covers “classical” PTPs, which are described next. PTPs utilize a 
cysteine as the main catalytic residue (Figure 1). Only Class IV does not follow 
this trend, as it utilizes an aspartic acid for catalytic activity without cysteine 
being present. 
Class I has 99 PTPs, which are divided into “classical” PTPs and VH1-
like PTPs. “Classical” PTPs were identified and isolated first, as can be deduced 
from their namesake. There are 38 “classical” PTPs which selectively 
dephosphorylate tyrosine residues.
19
 The first PTP to be expressed and isolated 
6 
was PTP1B, from the PTPN1 gene, and it is a “classical” nonreceptor PTP 
(NRPTP).
11
 This is opposed to the “classical” receptor-like PTPs (RPTPs), which 
are trans-membrane proteins. The Class I VH1-like PTPs contain several enzymes 
that can dephosphorylate residues other than tyrosine, including mRNA and 
phosphoinositides. Therefore they are also called dual-specificity PTPs (DSPs). 
 
Figure 1. Important residues for catalysis in “classical” PTPs (see Dewang, et 
al.).
18 
 
Of the other three classes included in the PTP family, only Class III has 
been implicated as a target for disease initiation to a significant degree for this 
discussion. This class is made of three PTP homologs designated cell-division 
cycle 25, or CDC25A, CDC25B and CDC25C. In addition to tyrosine, they are 
also capable of dephosphorylating phosphothreonine and phosphotyrosine of 
Cdks (kinases) that are needed for cell cycle progression. The CDC25s may arise 
from oncogenes because of their increased expression in several cancers,
20
 and 
they have been studied as therapeutic targets for several cancers.
21, 22
 The CDC25s  
have not been established as arising from oncogenes, however. 
7 
 Several genomic studies have been done to grasp a possible role for PTPs 
in disease initiation, progression, etc. Genetic deletions or overexpression of 
chromosomal locations in cancer cells have been used to implicate PTPs. While 
protein kinases, another signaling enzyme that phosphorylates proteins and other 
biomolecules, have been studied and established to arise from several oncogenes, 
as of 2012 only two PTP genes, PTEN and PTPN11, are recognized to have 
tumorigenic properties.
23, 24
 
PTPN11 is the gene that encodes the SHP-2 enzyme. This is a classical 
NRPTP that can cause juvenile myelomonocytic leukemia after a somatic 
mutation. The mutation results in a more active enzyme. This particular enzyme, 
SHP-2, has an auto-inhibitory tail that inserts itself into the enzyme’s catalytic 
pocket. The mutation results in a destabilized inhibitory interaction by changing 
the residues at or near the interface of the N-SH2 tail and the PTP catalytic 
domain. The mutation prevents the inhibitory tail from blocking the catalytic 
pocket causing increased RAS/MAPK signaling in certain cells. Furthermore, a 
germ-line mutation of SHP-2 causes Noonan syndrome, which is a developmental 
disorder. It too is a “gain-of-function” mutation with similar effects as the somatic 
mutations.
25, 26
 
The PTEN gene encodes the PTEN enzyme (or MMAC1). It is also part of 
Class I, but it is not a “classical” enzyme. Instead, it belongs to the VH1-like PTP 
subclass. PTEN specifically dephosphorylates phosphatidylinositol 3,4,5-
trisphosphate on internal cell membranes.
27
 In contrast to PTPN11, mutation of 
8 
PTEN in cancer cells results in a loss of function for the encoded enzyme. 
Therefore, PTEN is a tumor-suppressing gene when it is not mutated.
28
 
Discovering mutated, deleted or over-expressed genes provides a basis to 
further investigate their roles in tumorigenesis or tumor suppression with genetic 
experiments. Genetically modified mice are used to breed mice that express either 
one allele or no alleles, i.e. knockout mice, of a particular gene. These studies 
allow investigations of positive or negative effects that a gene may have on mice, 
which could translate to humans. In the case of Ptpn1
 
knockout mice, insulin 
sensitivity and a resistance to weight gain was observed when they were fed a 
high fat diet.
13
 This led to increased interest in PTP1B, the enzyme associated 
with PTPN1, as a pharmaceutical target and resulted in further investigations into 
its possible role in other diseases.  
A couple of studies were released in 2007 that related PTP1B to a proto-
oncogene in the epidermal growth factor receptor family (EGFR) known as HER-
2 (or ERBB2). HER-2 is a receptor tyrosine kinase that becomes cancerous when 
a point mutation occurs in the region encoding its transmembrane domain or when 
there is a deletion or insertion in the extracellular domain, ECD.
29
 HER-2 is 
overexpressed in about 25% of breast cancers,
30
 and overexpression of PTP1B has 
been associated with HER-2.
31
 
The study by Bentires-Alj and Neel
32
 utilized the mouse mammary tumor 
virus (MMTV) to promote the oncogenic form of ERBB2 with the 
transmembrane domain point mutation (MMTV-NeuNT). After breeding with 
Ptp1b knockout mice, less than 40% of the MMTV-NeuNT knockout mice, or 
9 
Ptp1b null mice, had developed tumors after ~ 3 years. In comparison, MMTV-
NeuNT mice with one or both Ptp1b alleles developed tumors with an average 
latency period of ~ 13 months. Furthermore, 80–90% showed tumor onset within 
~ 500 days. Finally, a separate mouse model was studied that would generate 
mammary cancer under the same MMTV promoter except it would be 
independent of HER-2. These mice, expressing polyoma middle T antigen 
(MMTV-PyMT), were crossbred with Ptp1b null mice. They showed no change 
in tumor onset when comparing the MMTV-PyMT mice that had one or both 
ptp1b alleles to the MMTV-PyMT Ptp1b null mice. In other words, Ptp1b is 
directly and specifically related to Her-2 facilitated tumorigenesis. 
In the Julien
29
 study, MMTV was also used, but it utilized the in-frame 
deletion of the extracellular segment of Erbb2 (this mutation is also called Neu) 
when breeding with Ptp1b null mice. Mice expressing this altered form of Erbb2 
develop mammary tumors that frequently lead to lung metastasis lesions and 
mimic similar events in human breast cancers. These changes are designated as 
NDL2 mice. After breeding, tumor onset was delayed for ~ 35 days for the mice 
that had one Ptp1b allele or by ~ 85 days for Ptp1b null mice.
33
 Furthermore, a 
decrease in lung metastasis was also noted in mice with one or zero Ptp1b alleles. 
PTP1B is generally not recognized as an oncogene (or proto-oncogene) despite its 
chromosomal location being amplified in some cancers. It only appears to have a 
complementary role that assists in the onset of some cancers. However, as a 
downstream signaling enzyme, targeting PTP1B to treat cancer may still be 
beneficial in combination therapy under the right circumstances. 
10 
In contrast to the Ptp1b null mice that showed obesity resistance, mice that 
were genetically modified to remove Ptpn2 did not experience a beneficial 
phenotype. Ptpn2 is a gene that codes for Tcptp. This is another ubiquitously 
expressed NRPTP, and it is very similar to PTP1B, with about 74% sequence 
identity in the catalytic domain (Figure 2).
34
 TCPTP is a protein that is vital for 
hematopoiesis, immune cell development and cytokine signaling. When mice are 
bred with knocked out Tcptp, they die in 3–5 weeks.35 However, there are two 
known active isoforms of TCPTP. A 45 kDa protein of TCPTP, which localizes in 
the nucleus, and a ~ 48 kDa protein of TCPTP, which is found mostly in the 
cytosol of cells, are both active.
36
 It is not currently known if inhibition of one 
form will be tolerated. In other words, inhibiting the nucleus isoform may be 
detrimental if its function is unique, but inhibition of the cytosol isoform may 
have overlapping phosphatases that can take over. The survival information from 
genetic deletion experiments may be misleading since both enzyme isoforms are 
missing. 
These two enzymes, PTP1B and TCPTP, have distinct physiological roles 
despite their sequence similarities based on the genetic deletion experiments. The 
design of inhibitors for PTP1B will necessitate testing for selectivity over TCPTP. 
However, there is some evidence that inhibition of TCPTP may be beneficial in 
limited cases.
37
 Additionally, two pseudogenes of TCPTP exist that can express 
inactive enzymes,
19
 which may somewhat reduce the selectivity requirement of a 
drug. If these inactive enzymes are produced and have no vital function, then their 
presence may act as a buffer for the vital and active TCPTP isoforms. It is certain, 
11 
however, that deleting PTPN2 entirely, and thus not generating the required 
enzymes, is not tolerated. 
 While a variety of other potential cancer targets exist in the protein 
tyrosine phosphatase family, the evidence and research are still accumulating.
15
 
Potential PTP cancer targets and tumor suppressing PTPs continue to be 
investigated. However, there is a large number of protein tyrosine kinases that 
have been designated as arising from oncogenes.
24
 Targeting of specific PTPs  
may complement PTK targeting and inhibition. 
Figure 2. PTP1B and TCPTP enzymes. Acquired from VAST
38
 and displayed 
using Cn3D.
39
 PDB databank codes are in parenthesis. TCPTP (1L8K) and 
PTP1B (1ONZ) with WPD loops in a box (TCPTP: tubes, PTP1B: balls and 
sticks) and catalytic cysteines circled. Other amino acids within ~ 5 Å of the 
catalytic cysteines are also shown. The protein backbone is shown in red 
(matching amino acids) or blue (not matching) wire. 
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1.4 Reported Inhibitors of Protein Tyrosine Phosphatases 
Because PTPs have an ionic binding pocket, developing drugs to interact 
within the pocket is difficult. Inhibitor interaction with the catalytic domain 
requires incorporation of ionic or polar functional groups, but compounds with 
these groups struggle to be cell permeable. Several early attempts at inhibition 
tried to incorporate a non-hydrolyzable phosphonate (Figure 3, DFP) to mimic 
tyrosine phosphates.
40, 41
  
 
Figure 3. Reported inhibitors of PTPs and general design. Difluorophosphonate 
(DFP); 2-(oxalylamino)-benzoic acid; General Inhibitor Design (GID) 
These inhibitor designs usually had various peptide attachments with the non-
hydrolyzable difluorophosphonate (DFP) group. These were used to analyze X-
ray structures for important interactions. Non-peptide structures were then 
synthesized after the X-ray studies and several assays. These non-peptide 
modifications were decent in vitro inhibitors, but the inhibition of the enzyme 
relied too heavily on the phosphonate group. 
In 2000, a set of reversibly competitive inhibitors was described by 
researchers at Novo Nordisk.
42
 These inhibitors utilized an oxalylamino group to 
mimic the phosphate and interact reversibly within the catalytic pocket. The initial 
structure used to probe the PTPs was just a benzene ring (Figure 3, OBA), but 
various other aromatic rings were also investigated. The ortho-substituted 
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carboxyl group was found to impart an important inhibitory effect, too. When 
these inhibitors were assayed with 7 PTPs (PTP1B, PTPβ, PTPε, PTPα, CD45, 
PTP-LAR and SHP1) using para-nitrophenyl phosphate (pNPP) as substrate, they 
could bind (Ki) PTPs at concentrations as low as 3.6 µM. A binding assay 
comparison was done between oxalylaminobenzene, i.e. ortho-carboxyl group 
absent, and 2-(oxalylamino)-benzoic acid (OBA). While OBA showed a Ki value 
of 23 µM against PTP1B, removal of the o-carboxyl group resulted in a Ki value 
>2000 µM under the same assay conditions. Additionally, X-ray analysis was 
done to compare these inhibitors to phosphotyrosine. PTPs undergo a 
conformational change of their WPD loop upon binding and hydrolyzing the 
phosphate group. The shift in the WPD loop from an “open” conformation to a 
“closed” conformation allows the aspartic acid (D181 for PTP1B) to act as a 
general catalyst.
43 
Initially, aspartic acid donates a proton to the phosphate 
targeted by the catalytic cysteine. The catalytic sequence is complete upon 
aspartate deprotonating an occluded water molecule that is responsible for 
removing the phosphate from the cysteine to reconstitute the catalytic form of the 
enzyme (Figure 1). 
Interestingly, the o-carboxy group of OBA was located very near (~ 2.9 Å) 
to the aspartic acid upon loop closure. Comparison of binding affinity at different 
pH values showed that OBA and its analogues bind 6–10 times better at pH 5.5 as 
opposed to neutral pH. This implies a potential salt bridge forming between the 
OBA analogues at low pH, and ionic repulsion at neutral pH. When several PTPs 
were assayed to find an optimum pH for catalytic activity,
44 only PTPβ had higher 
14 
turnover of pNPP at neutral pH as opposed to a pH below neutral. However, 
CD45 was the only PTP whose activity was found to be pH independent. 
 Inhibitors designed for this work attempted to utilize the ortho-carboxyl 
group in similar structures. However, the oxalylamino group that interacts 
reversibly and competitively is replaced in an attempt to incorporate an 
irreversible and competitive group (Figure 3, GID). The initial design would 
replace the reversibly binding oxalylamino with leaving groups. The R
1
 and R
2
 
groups would replace the carbonyls with mono-halogenated sp
3
 carbons. 
Additionally, R
2
 would have the sp
2
 halogenated product upon H-X elimination 
from R
2
 and R
1
, respectively. This would provide a halogenated Michael-acceptor 
for comparison to the halogenated alkyl analogue. Further design modifications 
from these initial tests were then going to be done by substitution on the aromatic 
ring and individual replacement of the two carboxyl groups shown in Figure 3 
(GID) with nitro groups. 
The selectivity of irreversible inhibitors is usually a greater concern 
compared to reversible inhibitors. Cellular nucleophiles and other 
macromolecules can be alkylated by irreversible inhibitors that are ambiguously 
active. If they are selective, however, then several issues can be overcome that 
reversible inhibitors face. Cellular expulsion is an issue that all inhibitors face, but 
a reversible inhibitor will face this issue each time it is released from its target. 
Furthermore, increased concentrations of a cellular substrate will influence the 
kinetics for binding of the reversible inhibitor. Additionally, cancerous cells that 
survive treatment with a reversible inhibitor could mutate to gain resistance.
45
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With regard to the general inhbitor design, several other inhibitors have 
been reported with these general structures. In fact, several precursor compounds 
of the planned inhibitors have been investigated in addition to similar analogues. 
In general, creating a reactive organic structure to bond with a PTP catalytic 
domain is focused on cysteine’s reactivity, but investigations of these precursor 
compounds have found that it is not always the reactive residue. 
 Inhibition by acrolein was investigated against PTP1B long after it was 
found to react with just cysteine,
46
 i.e. not in a protein. Cyclic products form upon 
a second reaction with another cysteine molecule. When PTP1B and acrolein are 
assayed together, PTP1B is inactivated. The enzyme activity is not recovered after 
gel filtration or dialysis to remove acrolein.
47
 Kinetic data and MALDI-TOF of a 
trypsin digested enzyme implicate the catalytic cysteine for the site of reaction. 
Therefore, all evidence points to acrolein being an irreversible and competitive 
inhibitor. Furthermore, molecules with similar functional groups were 
investigated to determine the likelihood of attack at the β-carbon over the 
carbonyl carbon. Crotonaldehyde, acetaldehyde and several other compounds 
showed little to no inhibition when assayed under similar conditions (Table 1). 
Acrolein is a small molecule that can align with the more electrophilic beta 
carbon near the nucleophilic cysteine. Inhibition is noticeably reduced when 
bulky substituents on acrolein’s beta carbon are substituted for a hydrogen. 
Additionally, small molecule aldehydes did not inhibit enzyme activity. This 
indicates a preference toward attack at the beta carbon of a conjugated carbonyl, 
16 
and it accounts for the reduced activity of alkyl-substituted acroleins, which will 
have reduced mobility inside the catalytic pocket to properly align.  
Table 1. PTP1B Inhibition by Small-molecule Aldehydes 
 
PTP1B (200 nM) with 500 µM of selected compound preincubated in assay 
buffer for 10 min with PTP1B enzyme. An aliquot was removed and used in an 
assay with pNPP as substrate (from Seiner, et al.).
47
  
 
 Compounds with unsaturated groups attached directly to an aromatic ring 
have been studied for their inhibition type and ability against PTPs, too. Cinnamyl 
aldehydes were shown to reversibly bind to the catalytic domain
48
 (Figure 4). 
However, a guanidine group of an arginine residue, close to the catalytic cysteine, 
was said to be forming an enamine in preference to undergoing a thiolate reaction. 
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Figure 4. Proposed mechanism of inhibition of PTP1B by cinnamyl aldehyde 
analogue (from Fu, Park and Pei, 2002).
48 
Evidence of this formation was provided by heteronuclear single-quantum 
correlation spectroscopy (HSQC) with two 
13
C labeled inhibitors on the aldehyde 
carbon (Figure 5, compound 14) and on the beta carbon, not shown. From Figure 
5, the aldehyde proton peak and its carbon peak from compound 14 shift upfield 
upon addition of PTP1B. The appearance of three new peaks was believed to be 
from the newly generated enamine. Furthermore, a mutational study replaced the 
catalytic cysteine with alanine, and similar results were obtained from the HSQC 
experiment. Kinetic data showed these cinnamyl aldehydes to be binding slowly 
and reversibly as competitive inhibitors. 
 The cinnamic acid peptide matching the aldehyde compound was 
previously made by a separate group, and it was far more effective at inhibiting 
PTP1B, 0.079 µM
49
 compared to ~ 5.42 µM
48
 for the aldehyde. Detailed 
inhibition analysis was not described and no further published work could be 
found on the cinnamic acid analogue. While speculative, its inhibition may have 
been more favorable as a phosphate mimetic interacting with the cysteine, as 
opposed to reacting with guanidine. 
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Figure 5. HSQC analysis of peptidyl cinnamaldehyde. A, compound 14 only; B, 
1:1 of 14:PTP1B; C, 2:3 of 14:PTP1B. Spectra on the right, 2:5 of 14: PTP1B 
mutant, C215A; Figure 5 and 6 from Fu, H. et al., 2002.
48
 
 
 Another unique example of inhibition was proposed for trans-β-
nitrostyrene (TBNS) and its analogues by the same author that studied the 
cinnamyl aldehydes.
50
 A nucleophilic addition reaction with the electrophilic β-
carbon may be expected, but this seems not to be true. UV experiments were done 
to confirm the loss of its large nitroalkene peak at 320 nm with β-mercaptoethanol 
present. However, the same was observed when the experiment was repeated 
using PTP1B, although on a slower time scale. Again, HSQC experiments were 
performed, this time with the carbon attached to the nitro group labeled (Figure 6, 
compound 10). The reaction with β-mercaptoethanol has peaks moving very far 
upfield for both 
1
H (~ 3 ppm shift) and 
13
C (~ 100 ppm shift), from about δ 8 to 5 
ppm and δ 145 to 45 ppm, respectively. When PTP1B is present, the HSQC 
upfield shifts for 
1
H and 
13
C are only about 1 ppm and 10–15 ppm respectively. In 
other words, the carbon-carbon double bond seems to remain intact when PTP1B 
is present, but a reaction or interaction with the inhibitor is occurring.  
19 
Figure 6. HSQC of peptidyl nitrostyrene. A, only compound 10; B, 1:2.4 of 
10:PTP1B; C, 1:3.33 of 10:β-mercaptoethanol (from Park and Pei, 2004).50 
 
 Additionally, kinetic assay and mutation studies were done to verify the 
location of the binding at the catalytic cysteine. Mutation of C215S did not show 
peaks corresponding to the free inhibitor (i.e., compound 10 in Figure 6, A) or 
peaks indicating binding in any fashion. The authors state that ESI-MS was done 
on this mutant, and they found up to three TBNS additions. This led them to 
conclude that addition by surface residues occurred, which sufficiently scattered 
the NMR signal. However, a C215D mutation is known to be slightly catalytic 
toward pNPP. Another HSQC experiment returned similar plots as Figure 6, B; 
only the two peaks at about δ 7.5 ppm for 1H and δ 130 ppm for 13C were 
observed, however. This evidence led to the proposed slow-binding, reversible 
inhibition to the catalytic cysteine shown below (Figure 7). 
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Figure 7. Proposed mechanism of inhibition for TBNS analogues (from Park and 
Pei, 2004).
50 
 
 Nitrostyrene natural products and derivatives have previously generated 
interest as potential anti-cancer agents,
51
 and they have received recent interest 
from drug development and marketing companies.
52
 Several nitrostyrenes were 
designed and investigated for their ability to specifically inhibit PTPs. A 
mechanistic investigation for enzyme inhibition was not described, but there is 
evidence that these analogues may have a future as PTP inhibitors. 
 The inhibitor design has the potential to react with a nucleophilic cysteine 
thiol, which may form an episulfonium ion. While there is evidence for 
compounds that can create episulfonium ions intramolecularly,
53
 there is only 
speculative evidence for this ion formation to be biologically relevant. However, a 
recent investigation of α-bromocyclopentenone possibly forming an episulfonium 
ion prior to being reactive has been reported (Scheme 2).
54
 Some natural products 
contain this α-haloacrolyl group in their structure, and the authors were 
investigating a reason for their bioactivity.  
 A proposed mechanism was developed in which a cellular thiol reacted 
with the cyclopentenone, like a typical Michael acceptor. An episulfonium ion 
21 
formed upon displacement of bromide, which is followed by nucleophilic attack 
by a DNA fragment. The α-bromocyclopentenone did not react with the DNA 
fragment after extended pre-incubation with thiol, however. When α-
bromocyclopentenone was treated with only a DNA fragment, there was no 
detectable reaction between them (by Maxam-Gilbert analysis). This and 
additional evidence led the authors to conclude that the thiol is needed for 
reaction. Episulfonium ion may be forming, but it is reacting immediately. 
Extended incubation with the thiol is likely creating an inactive product (Scheme 
2, far right structure). 
Scheme 2. Proposed episulfonium ion from α-bromocyclopentenone 
 
 
 While this simple structure provides for the possibility of an episulfonium 
ion forming under biological conditions, its targeting of DNA is not desirable for 
the inhibitor design. Preferably, the designed inhibitors will selectively inhibit an 
enzyme, like PTP, instead of damaging DNA. Most of the inhibitors to be 
described either have halogenated alkyl groups or halogenated Michael-acceptor 
functionality or something very similar. However, the reactivity of α-
bromocyclopentenone is just a simple example of a possible mechanism for more 
complex structures. Thus, further investigations would be needed to elucidate 
their inhibition toward enzymes or DNA. 
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2 DESIGN AND SYNTHESIS OF HALOGENATED COMPOUNDS 
2.1 General Inhibitor Design 
Design of the irreversible inhibitors incorporated the o-carboxyl group and 
modified the oxalylamino subsituent. The reversible binding of this group is 
modified to make a stable, irreversible bond with the catalytic cysteine of PTPs. 
Modifications of the starting material 2-carboxycinnamic acid (2-CCA) will 
involve adding or substituting halogens to the alkene and substitution on the 
aromatic ring. Occasionally, a halogenated lactone forms and lactone alkenes are 
also obtained from these substances. For clarity in discussing the variety of 
reactions with the 2-CCA analogues, a numbering scheme is provided (Figure 8) 
and will be referred to within the text. A similar numbering scheme will be used 
when describing the nitrolactones for consistency. It should be noted that the nitro 
group is in place of the first carbon of analogous 2-CCA compounds. However, 
the only relevant substitutions occur on the labeled carbons.
 
Figure 8. Numbering scheme for cinnamic and nitrolactone analogues. In the text, 
references to these structures will be made by simply stating relevant changes 
with respect to the carbon and the associated number, e.g., substitution of iodine 
at C7. 
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2.2 Halogen Addition to Analogues of Cinnamic Acid 
Scheme 3. Synthesis of 2, 14 and 24 
 
R = H, R
1
 = COOMe (1)    R = H, R
1
 = COOMe (2) 
R = H, R
1
 = NO2 (13)     R = H, R
1
 = NO2 (14) 
R = I, R
1
 = COOH (21)    R = I, R
1
 = COOH (24) 
 
 The first set of compounds was made by halogen additions to 2-
carboxycinnamic acid (2-CCA). Chlorine and bromine are known to be good 
leaving groups in nucleophilic displacement reactions. Chlorine forms a stronger 
covalent bond to carbon in comparison to bromine, and that bond strength may 
make it a better candidate for future drugs. Problems arise for any potential 
inhibitors that are ambiguously active in vivo as opposed to active only upon 
entering the correct environment. In this case, the ideal reactivity would arise 
upon entering the catalytic-binding pocket of PTP and nowhere else. 
 Synthesizing the halogenated compounds without esterifying one of the 
acids of 2-CCA was problematic since it is not soluble in many organic solvents.  
The diester product 1 (Scheme 3) is soluble in organic solvents like 
dichloromethane (DCM). Standard methods used to add chlorine across an olefin 
rely on bubbling dangerous chlorine gas into an organic solution with the olefin 
dissolved. A new synthetic route was desirable to avoid excessive use and 
24 
exposure to this gas. Some reactions that generate radical chlorine or a small 
amount of chlorine gas in situ were attempted. 
 Two promising synthetic procedures failed to produce the desired 
addition. A hydrogen peroxide or organic peroxide solution was reported to add 
chlorine across an olefin when hydrochloric acid was present.
55
 Another synthesis 
replaces the peroxide with an N-chloro organic reactant, Chloramine-T, to effect 
the same addition;
56
 the conditions are similar to an Orton rearrangement. Both 
reactions supposedly generate a small amount of chlorine, in situ, that remains 
dissolved in the reaction solvent. No chlorine addition products were observed  
with 2-CCA (peroxide reaction attempted) or 1 (both reactions attempted).  
A unique reaction mixture of potassium permanganate, organic chloride 
and trimethylsilyl chloride was the most successful reaction mixture, but it 
proceeds by an unknown route.
57
 An oxidizing agent, potassium permanganate, is 
stirred in the presence of an organic ammonium chloride salt and a large amount 
of chlorotrimethylsilane to generate an emerald green solution capable of chlorine 
addition across a carbon-carbon double bond. Because DCM is used as the 
reaction medium, 2-CCA could not be used, as it is completely insoluble. The 
diester analogue 1 is soluble, and it afforded the desired addition of chlorine to the 
carbon-carbon double bond. 
When 1 was added to the green solution, doublets appeared between δ 6.7 
and 4.6 ppm in the NMR spectrum of the crude material. However, the progress 
of the reaction was not easy to monitor visually as the emerald green solution 
never seemed to fade or discharge its green color. This was reported to occur at 
25 
the end of some reactions, but it did not in this case.
57
 A dark colored emulsion 
typically formed as a lower layer, however. Thin-layer chromatography (TLC) 
showed a few spots developing along with the remaining starting material at the 
onset, but several spots appeared when lengthy (several hours) reaction periods 
were allowed. The by-products that seemed to form were the lactone ester (8 see 
Scheme 5), possibly monochlorinated lactone ester (11 and/or 12, see Scheme 7), 
and the diastereomer of 2. These by-products are seen in NMR spectra of crude 
material measured during the numerous syntheses, and confirmation of their 
appearance is based on individual isolation in later syntheses. 
The dichloro product 2 could form as 4 stereoisomers. These are from two 
sets of enantiomers that would also be diastereomers of each other. Racemic 
mixtures of each diastereomer form since the reaction does not have any chiral 
solvents or reactants. The isolated product 2 forms as one set of doublets in the 
1
H 
NMR with CDCl3 that are separated by almost 2 ppm (δ 6.62 and 4.75 ppm, J = 
10.4 Hz). In comparison, addition of chlorine to cinnamic acid produces a set of 
doublets separated by less than 0.5 ppm.
58
 The doublets for 2 appeared in a 6:1 
ratio, by integration, with another set of doublets near them. This less abundant 
isomer (δ 6.67 and 5.12 ppm, J = 4 Hz) accounts for the bulk impurity.  
When the carbon-carbon double bond was not adjacent to an aromatic 
ring, anti addition of chlorine was said to occur exclusively.
57
 In the one reported 
case of a carbon-carbon double bond adjacent to an aromatic ring (trans-stilbene), 
an equivalent mixture of anti-to-syn addition was found. One diastereomer 
predominated during synthesis of 2, but the stereochemistry, i.e. anti or syn 
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addition, was not determined. While 2 formed with this unique synthetic reagent, 
the isolated yield of pure product typically fell between 40–60%. The amount of 
green reagent solution was doubled and quintupled relative to 1, but yields did not 
improve with the excess.  
Scheme 4. Synthesis of 4 and 23 
 
R = H, R
1
 and R
2
 = Me (1)   R = H, R
1
 and R
2
 = Me (4) 
R = I, R
1
 = H, R
2
 = Et (20)   R = I, R
1
 = H, R
2
 = Et (23) 
 
Addition of bromine to 1 in DCM produced 4. While the diacid analogue 
of 4 has been reported (i.e. Scheme 4 if the product has R, R
1
 and R
2
 = H)
59
, this 
diester was made for comparison purposes to 2. Also, future substituents were 
going to be incorporated into the aromatic ring in the future, and a direct 
comparison to the unaltered ring was desired. Instead of the well-resolved 
doublets seen when 2 was isolated, broad peaks centered at δ 6.8 and 4.9 ppm 
appeared in the NMR spectrum of 4. Elemental analysis did confirm that the 
bromine addition occurred, however. Side products rarely formed in these 
syntheses, and the product was acquired in very high yields. 
Inhibitors with functionally useful carboxyl groups that are esterified are 
generally considered prodrugs. The esters can be hydrolyzed to their acid form by 
esterases in vivo. Then they may proceed to interact within the ionic binding-
27 
pocket of PTPs more efficiently. Unfortunately, having only the prodrug for in 
vitro enzyme-only inhibition assays is not an ideal case as esterases are not 
present. 
Synthetic procedures were devised to retain the phenyl carboxyl group 
while making an ester of the propenoate carboxyl group, C1 (Figure 8). A single 
ester should retain the solubility characteristics needed for synthetic 
transformations, and the phenyl carboxyl group was a noted feature for inhibitory 
activity in OBA. The o-carboxyl group's proximity to C3 of the propenoate chain 
allows for cyclization to a lactone when the compound is heated in acid. After 
cyclization, the free acid at C1 could be made into the ester, and the lactone could 
be reopened to free the o-carboxyl group. 
Scheme 5. Synthesis of 7 followed by 8 and 9 
 
              R = Me (8), Et (9) 
 When 2-CCA was refluxed in polyphosphoric acid and acetic acid 
(Scheme 5), the lactone 7 formed in quantitative yield. A white solid precipitated 
from cold water and was collected by filtration. Esterification of the free carboxyl 
group proceeded in good yield as long as the cesium carbonate base was used 
sparingly. When using > 0.8 molar equivalents of cesium carbonate was used, the 
lactone would open and that resulted in the phenyl carboxylate being esterified 
too.  
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 After esterification, reopening the lactone was usually done with 
triethylamine or DBU in suitable solvent (chloroform or DCM). Running the 
reaction neat with triethylamine provided the product. However, monitoring the 
reaction's progress by TLC was cumbersome without solvent. Some time was 
needed for either procedure, but typically yields were high. Also, any unreacted 
lactone was easily separated from product and could be reused with another 
procedure.  
 Aromatic substitution with iodine was also possible from 7. This 
procedure, which is described later (see Scheme 8), provides compound 15. 
Similar steps were taken to isolate the lactone ester analogues (17 and 18), and the 
subsequent alkenes (20 and 21) that were acquired prior to halogen addition (see 
Experimental). 
The chlorination reaction that provided 2 was used to make 24 (see 
Scheme 3) after minor adjustments. Analysis of crude material from a room 
temperature reaction showed what may be two sets of ring closure doublets, 
similar to 11 and 12 (Scheme 7), that formed in a 1:1:2 ratio with the major 
product being 24. The synthesis was repeated on an ice bath, which decreased 
lactone products and favored the desired chlorine-addition product. After 
purification by column chromatography and recrystallization, 24 was isolated in 
low yields, consistent with yields of 2 over several syntheses. Increasing the 
chlorinating reagents did not improve yields. In fact, doubling the chlorinating 
reagents at cold temperatures seemed to increase ring closure products. 
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Similar to the synthesis of 4, simply adding bromine to a solution of 20 in 
DCM led to the previously unreported compound 23 (see Scheme 4). While the 
crude NMR spectrum did show signs of side products formation, they are in much 
smaller quantities when compared to the product. There were broad peaks in the 
1
H NMR spectrum of 23 at δ 6.82 and 4.81 ppm instead of defined doublets, 
similar to what was observed with 4. Elemental analysis confirmed that the 
desired product 23 formed. 
A nitro group replacement of the o-carboxyl group, C10, was investigated 
with the chlorination reaction too (Scheme 3, 14). The nitro group is isoelectronic 
to the carboxylate ion that is part of the oxalylamino benzoic acid, OBA. 
However, it is electronically neutral while still having partially charged oxygens 
capable of interacting with the binding pocket of enzymes. This will also allow 
the nitro compound to be more soluble when in aqueous solutions. While the 
carboxyl group does benefit similarly when in the ionic form, it is also less 
soluble in organic solvents needed to make necessary modifications of the 
structures. Esterification does alleviate this problem, but esterases are then 
necessary to hydrolyze these esters, in vivo, before the carboxylate becomes 
available. 
Acid-catalyzed esterification of the lone carboxyl group (C1, Figure 8) 
provided the more soluble methyl ester 13 prior to submission to the chlorination 
reaction (Scheme 3). The chlorine-addition reaction was monitored by TLC, 
which showed starting material remaining with suspected product spots over long 
periods; additional spots did not appear as they did when 2 was made. 
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Furthermore, the emerald-green solution color did fade somewhat as the reaction 
progressed, along with accumulation of a brown precipitate. Addition of more 
TMSCl along with agitation of the reaction mixture by use of a pipet returned the 
solution to a greenish color. However, the reaction did not progress to completion, 
as judged by TLC. When a second equivalent of the chlorinating reagents was 
added, the reactant spot disappeared more quickly. The highest-yield procedure 
involved addition of 2.5 equivalents of the chlorinating reagents in portions before 
the starting material spot disappeared on TLC completely. 
1
H NMR of the crude 
showed 14 had formed almost exclusively with a very small amount of unknown 
material. Unlike syntheses of 2 and 24, this procedure yielded ~ 82% of the 
desired product as slightly impure crude prior to purification steps. The spots 
deemed to be product 14, after separation by column chromatography, were 
recrystallized to yield 32% of pure product. Additional spots collected from the 
column were not analyzed further. 
2.3 Halogenated Alkenes as Michael Acceptors 
The susceptibility of an carbon-carbon double or triple bond to 
nucleophilic attack increases when it is conjugated to electron-withdrawing 
groups like carbonyls, nitro groups, cyano groups, etc. Nucleophiles favor 
reacting with C3 (Figure 8), the β-carbon from the withdrawing group, because 
electron density is removed from it via resonance. The carbon-carbon double 
bond of 2-CCA is already a weak Michael acceptor, but halogen addition removes 
the Michael acceptor functionality. Michael-acceptor molecules are known to be 
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good at forming covalent bonds and some have demonstrated an ability to react 
with a cysteine.
47
 Reactive sulfhydryl groups of proteins have been probed by 
using Michael acceptors like N-ethylmaleimide, which forms a bond that is stable 
to hydrolysis.
60 
Isolation of an alkene substituted with halogens could lead to 
novel inhibitors. 
Scheme 6. Synthesis of 3 and 5 
 
X = Cl (2)     X = Cl (3) 
X = Br (4)     X = Br (5) 
For compound 2, there are two possible hydrogen chloride eliminations. 
The favored elimination involves the hydrogen on C2 and the chloride on C3 (See 
Figure 8). The hydrogen on C2, nearer to the carboxy ester, is more acidic and 
preferentially removed by basic solvent. Two unique singlet peaks are 
distinguishable in the NMR from olefinic protons, which are attributable to the cis 
or trans isomer forming. These two singlets are located at δ 8.47 and 7.80 ppm (in 
CDCl3). The product with the singlet further downfield was the major isomer in 
every reaction, but the difference in the integration of the two singlets was smaller 
when using potassium carbonate as the base. When 2 was isolated and 
triethylamine used for the elimination reaction, the singlet located at δ 8.47 ppm 
appeared at much greater intensity. The reaction was run below 0°C and at room 
temperature, but both crude products’ NMR spectra show nearly a 10:1 ratio of 
32 
the singlets at δ 8.47 to 7.80 ppm. After isolation of the major isomer 3, X-ray 
crystallography confirmed that the Z-alkene preferentially formed.
61
 
The dibromo compound 4 was treated with base too, but unlike the 
elimination seen with 2, the dehydrobromination resulted in both E- and Z-alkene 
products appearing in ratios less than 10:1. Attempts were made to isolate both 
products for testing, but only 5 was isolated in sufficient purity to be cell tested, 
whereas 6, the other isomer, was only partially purified.  
There are similarities when comparing 5 to 3 which leads to the 
conclusion of 5 being in the Z configuration. The downfield singlet for the 
olefinic proton of 5 is further downfield than the olefinic proton of 6 ( δ 8.66 vs. 
7.99 ppm). This is similar to 3 having the furthest downfield singlet from its 
olefinic proton in comparison to the E-isomer. Furthermore, the two methyl ester 
singlets for 3 and 5 appear almost as a doublet (about 0.015–0.019 ppm separation 
vs > 0.3 ppm separation for the methyl esters of 6) and both 3 and 5 were the low 
spots on TLC. 
2.4 Halogenated Lactones of Cinnamic Acid Analogues 
While the chlorine-addition to alkenes was effective on both 1 and 21 
(Scheme 3), the same did not hold true when starting from 10 (Scheme 7). 
Unfortunately, chlorine-addition to the alkene of 10 was not favored. NMR 
analysis of crude reaction mixtures shows that the addition does not occur without 
by-products forming equally or preferentially. Chlorine addition across the 
carbon-carbon double bond was less favored than a single chlorine adding on the 
33 
propenoate, at C2, followed by ring closure to the lactone (Scheme 7). Overall 
this would be a substitution. 
Scheme 7. Synthesis of diastereomers 11 and 12 
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This reaction was run similarly to the previous synthesis for 2. The NMR 
of a crude reaction mixture after 1 hour showed evidence of 4 recognizable 
products, as follows: diastereomers 11 and 12, the desired chlorine-olefin addition 
product and compound 8 (see Scheme 5). The small amount of compound 8 
observed in the NMR spectrum may have already been present in the starting 
material and not generated from the reaction conditions. The formation of 11 and 
12 causes the carboxylic acid proton to be lost to solution, making it available to 
generate 8. 
Unfortunately, the crude masses acquired from these syntheses were 
substantially smaller than the starting material mass despite products forming with 
an added chlorine. Cold temperature reactions were utilized to investigate if 
chlorine-addition products to the alkene would increase; if chlorine addition 
precedes the formation of 11 and 12, then it may be kinetically favored. A 
1
H 
NMR spectrum of the cold reaction’s crude material showed the suspected chloro 
lactone formed in either the same amount as the dichloro addition or in greater 
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amounts. The crude mass was still lower than the starting alkene's mass under 
colder conditions, too. 
Complete separation of the two chloro lactone diastereomers 11 and 12 
from one synthetic procedure was accomplished. Yield of each diastereomer was 
only 17% and 10% of the theoretical yield when calculations are based on their 
formation instead of the dichloro product. The doublets for the chloro lactones are 
usually closer together with a smaller coupling constant when compared to the 
non-lactone analogues, i.e. 2 and 24 (Figure 9). Additional confirmation by IR 
spectroscopy showed no evidence of a carboxylic acid. A fairly broad carbonyl 
peak centered at 1763 cm
-1
 is at a slightly higher energy because of the ring strain. 
 
 
Figure 9. Doublets for chloro lactones, 11 and 12, shown with 24 for comparison. 
Expanded on the region δ 6.7 to 4.0 ppm (top to bottom: 11, 12 and 24). 
 
Because a mechanism for this green-colored, chlorination reaction has not 
been thoroughly investigated, chlorine addition across the carbon-carbon double 
bond prior to lactone ring formation cannot be ruled out. The carboxyl group 
(C10) is not expected to be a good nucleophile, at least not enough to displace a 
chloride. An initial addition of a single chlorine atom to the carbon-carbon double 
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bond may result in a resonance-stabilized benzyl cation intermediate (a 
chloronium intermediate is not expected). Competition between a second chloride 
attack or lactone ring formation at C3 would then occur, with the latter leading to 
the products seen in NMR analysis of crude material (Figure 9). 
Substitution of a hydrogen by an iodine on the aromatic ring was first 
attempted with 2-CCA as the starting material. Because electrophilic iodine is 
created in the reacting solution, it would be expected to react with the carbon-
carbon double bond, too. While 2-CCA was not soluble in organic solvents for 
chlorine and bromine reactions, it is soluble in the concentrated sulfuric acid 
solution used to generate the iodine electrophile. However, the reactivity of 2-
CCA seemed greatly reduced in comparison to the reported compounds,
62
 but one 
unique product was isolated that made this reagent worth further pursuit. A very 
small yield of one product had iodine substitution on the aromatic ring, in the 
desired para position, or C7 in Figure 8. Iodine was also added to the carbon-
carbon double bond with subsequent ring closure as an overall substitution, 
similar to 11 and 12. This is also similar to the polyphosphoric acid assisted 
reaction to form 7 (see Scheme 5), with electrophilic iodine instead of a Brønsted 
acid. 
Unfortunately, the crude material resulting from 2-CCA reaction with the 
electrophilic-iodine reagent is insoluble in organic solvents making it difficult to 
analyze and separate. The entire reaction mixture was subjected to the 
esterification conditions used to make 1, i.e., acetyl chloride in methanol to 
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generate HCl in situ, which allowed for easier separation and identification of the 
product, 26 (Scheme 9). 
More careful procedures were devised to individually isolate the variety of 
products from this electrophilic iodine substitution reaction. Starting from 7 
removes the double bond that competes with the aromatic ring for substitution. 
The acidic reaction mixture that creates the electrophilic iodine has a simple 
workup (“green”) that involves dilution with water and filtration of the organic 
product that precipitates. The desired product 15 did precipitate but only in 30–
50% of the theoretical yield (Scheme 8). On one occasion, excess reagent was 
made for the reaction that usually contained 110% total moles of I
+
 coming from 
iodine and sodium iodate.
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 The amended procedure used 140% excess of I
+
 in 
this example, and it yielded 61% of 15 upon purification. Extraction of the 
aqueous filtrate with organic solvent typically yielded another 30% of material in 
which the iodine was substituted in either the para or ortho position (C7 and C9, 
Figure 8) of the ring, along with a small amount of starting material, 7. The ortho-
substituted isomer was isolated, albeit in fairly low yields (see Experimental, 16). 
Scheme 8. Synthesis of 15 
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 An attempt to force the equilibrium to favor products was also made by 
adjustment of the conditions and periodic analysis of reaction mixture aliquots by 
1
H NMR. Regardless of the addition of more electrophilic-iodine reagent or gentle 
heating over several hours, starting material peaks always appeared in the 
spectrum from the seven aliquots, which were taken at various times during the 
reaction. While the peaks associated with compound 7 decreased with added 
reagent and heating, the reaction also became much darker black. In summary, a 
1
H NMR of an aliquot showed ~ 20% of compound 7 present after the reaction 
was allowed to stir overnight. There was still between 14–17% of compound 7 
present with excess reagent added. Heating the solution did not seem to reduce the 
amount of 7 any further, and it may have been causing the reactant, products or 
iodine reagent to decompose. 
From 15, the ethyl (17) and methyl ester (18) were made, similarly to what 
is shown in Scheme 5. Bulky amine bases were used to open the lactone and 
reform the alkene (ethyl ester 20 or methyl ester 21) prior to making the dichloro 
and dibromo products, 23 and 24 respectively (see Schemes 3 and 4). However, 
treating the alkene (20 or 21) with the electrophilic-iodine reagent provided 26 
(Scheme 9 with R = I). 
Scheme 9. Synthesis of 25 and 26 
 
 R = H (25), I (26) 
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When treating 1 with the electrophilic-iodine reagent, 25 formed almost 
exclusively with very little aromatic iodine substitution (Scheme 9). The aryl ester 
is cleaved by the electrophilic-iodine reagent (C10 in Figure 8) to help form the 
lactone. Regardless of the amount of electrophilic-iodine reagent used, little to no 
aromatic iodine substitution occurred. Compound 1 was used in place of 2-CCA 
because working with the crude mixtures from the 2-CCA syntheses was 
problematic, and the crude products were typically esterified anyway to allow for 
easier separations. 
Except for a few instances in which the molar equivalents of electrophilic-
iodine reagent were increased, the reaction conditions were not varied greatly in 
an attempt to force a second substitution and acquire 26. Heat and extended 
reaction times did not improve aromatic substitution when 15 was being 
synthesized, and the same result would be expected for 25 after it is formed in situ 
from 1 and the electrophilic-iodine reagent. Another route to the formation of 26 
was found by simply resubmitting the recovered crude, i.e. mostly 25 and other 
aryl-iodo isomers, to fresh electrophilic-iodine reagent. Because of the ease of 
workup and good yields post-synthesis of 1 and 25, this was the most used 
method to isolate 26 (see Experimental). 
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2.5 Lactone Alkenes of Cinnamic Acid Analogues 
Scheme 10. Synthesis of 27, 28 and 29 
 
R = H (25)    R = H (27, Z; 28, E) 
R = I (26)     R = I (29, E; 30, Z) 
 
Because compound 25 could be recovered in high yields, it was tested first 
with bases under varying conditions to open the lactone to generate a halogenated 
Michael acceptor. If the lactone ring opened, a singlet peak was expected to 
appear in the aromatic region, similar to 3. Furthermore, the doublet peaks seen in 
the 
1
H NMR for 25 would disappear. Iodine’s large size imparts a long bond 
length with carbon and allows it to stabilize the anionic iodide after bond 
breaking. This makes it a good leaving group. Therefore, dehydroiodination to 
form the lactone-alkene products, depicted in Scheme 10, was undesired but 
expected as a possibility as this same issue was encountered with a similar bromo 
lactone.
59
 
Sodium methoxide in methanol and triethylamine in dichloromethane 
were tried first. Sodium methoxide is a small base that can deprotonate 25 if the 
large iodine and carbomethoxy crowded the hydrogen on C2. Triethylamine was 
used as a bulky base if the steric crowding was irrelevant. While both reactions 
were monitored by TLC until apparent completion, the sodium methoxide attempt 
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was still incomplete by NMR. It appears as though the doublets of 25 are present 
along with a new set of doublets right next to them. The doublets of 25 are at δ 
5.65 and 4.78 ppm, and the new doublets are at δ 5.69 and 4.64 ppm. Methoxide  
was either reacting with 25 by substitution, SN2, and replacing iodine with 
methoxy, or the alpha proton was being abstracted and replaced to form the 
previously unseen diastereomer of 25. A peak for methoxy could not be 
confirmed as being present in NMR spectra of crude material, however. While 
only one product formed during the attempts to synthesize 25 (Scheme 9), another 
isomer is feasible. It is possible that only one diastereomer is favored after work 
up of the electrophilic-iodine reaction. Treating 25 with a small base allows for 
the other product to appear because reversible deprotonation does not favor one 
isomer.  
There are small singlet peaks present in the spectrum, but one in particular 
is found around δ 8.56 ppm. This peak is very small, but it could be from the 
lactone ring opening to provide an iodine-substituted Michael acceptor product 
that was not isolated, i.e. elimination of the C2 hydrogen with subsequent lactone 
opening (similar to 3 and 5). Between this singlet and the doublets for the starting 
material, 25 may be more stable or forming upon workup with acidic solutions. 
The singlet is less than 8% of the area of the smaller doublet arising from protons 
on C2 or C3 of 25 and its suspected diastereomer. 
When triethylamine was used prior to distillation and being dried, the 
reaction mixture was allowed to stir overnight because TLC monitoring seemed to 
show no reaction occurring after a few hours. Only one spot appeared on TLC the 
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next day, but this time it was at lower Rf than the spot for 25. Purification of the 
crude material by column chromatography was followed by NMR examination of 
the material of the corresponding spot, which was later purified and identified as 
27 (Z-alkene). A smaller set of peaks appeared with the column-collected 
material, too. Three peaks that integrate equivalently are as follows: a broad 
peak/singlet located at δ 6.54 ppm, along with nearly equivalent doublets at δ 3.20 
and 2.88 ppm (J = 16 Hz); the magnitude of the coupling constant points to these 
signals arising from geminal protons. A large singlet that integrates as 3 protons is 
also located at δ 3.82 ppm. A hypothesis is that this product could be a result of 
hydroxide attack on C3 of 27 followed by proton transfer to the C2. The alcohol 
either remains or forms a ketone (Figure 10), thereby opening the lactone. This 
compound was collected by column chromatography in slightly pure form as the 
material that came out right after 27. 
 The TLC spot for 25 had a similar Rf as the E-alkene 28. The E-alkene 
may have been appearing immediately with appearance of the Z-alkene over time, 
i.e. equilibration. NMR analysis of the reaction mixture was not done at the onset 
because analysis of a previous sodium methoxide reaction showed the reaction 
was incomplete. Hence, longer reaction times were thought to be needed, which 
probably allowed for additional by-products to form. 
 Because 26 was more difficult to make and purify, fewer eliminations 
were attempted with it. Distilled and dried triethylamine was used neat at room 
temperature and with slight heating. Additionally, ethyl acetate was used once as 
a reaction solvent with the thought that any lactone-opened product would be 
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insoluble in it and precipitate out of solution. Cesium carbonate in acetonitrile 
was used one time as well. Regardless, the desired lactone-opening reaction did 
not occur. Similar to 25, reactions with compound 26 showed singlets appearing 
around δ 6 ppm (for 29 and the Z-isomer, 30) along with several other peaks, 
indicating many side reactions.  
 One by-product was isolated, after use of cesium carbonate, that had the 
expected aromatic and methyl ester peaks for 26 without a singlet peak around δ 6 
ppm due to the olefinic proton. Instead, two equivalent doublets located at δ 2.86 
and 3.15 ppm appeared (J = 16.4 Hz for both). This is similar to the by-product of 
25 except there is not an easily distinguishable broad peak near δ 6.5 ppm, 
expected for the alcohol proton (Figure 10). Regardless, these doublets are 
expected to be arising from two hydrogens located between the newly formed 
aromatic ketone and the terminal methyl ester (Figure 10) with either a hydroxyl 
attached at C3 or possibly iodide reattaching instead of hydroxide (not shown). 
 
Figure 10. Possible by-products from elimination reactions with 26.Tautomers 
are shown after HI elimination. The one on the right may be favored when C7 has 
an iodine, thereby extinguishing a broad alcohol peak at δ 6.5 ppm. The left may 
be favored when the iodine on C7 is replaced by hydrogen. 
 
 Although HI elimination resulted in a few products that were later cell 
tested, the elimination reactions were inefficient. More efficient synthesis of 27 
and 28 have been described without requiring an iodo lactone.
63, 64, 65
 The reaction 
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starting from 26 produces 29, which is a novel compound, but the reaction 
conditions were adjusted to push the reaction toward lactone opening. This 
ultimately caused reduced yields. More careful control would be needed for a 
future synthesis to prevent side reactions with 29 and its isomer. Unfortunately, 
the Z-isomer (see Experimental, 30) was not sufficiently purified to be cell tested 
when the other compounds were submitted. A more suitable synthesis would 
likely need to be devised for these compounds if additional transformations are 
planned. 
2.6 Synthesis of 3-Nitromethylphthalide Precursors 
The last set of compounds synthesized replaced the carboxylic acid on the 
alkyl chain with the isoelectronic nitro group. Nitro groups are also very strong 
electron-withdrawing groups, which will make alpha hydrogens more acidic. This 
is important because, in neutral and acidic solutions, the 3-nitromethylphthalide 
(Scheme 11) prefers to cyclize into the five-membered lactone.
66, 67
  
Scheme 11. Synthesis of 31 
 
 These reports corrected an assumption by Hashimoto, et al. (1960) that 
provided for the possibility of acquiring an isomer of 31 that is in the open, or 
non-lactone form.
68
 While 2-CCA could be isolated as its lactone and readily 
44 
returned to the non-lactone, the nitrostyrene analogue will remain in the 
lactonized form unless it is in an alkaline solution. If in vivo conditions are neutral 
or acidic, then the reactive, Michael-acceptor olefin will essentially be hidden and 
thus unavailable to react with nucleophiles in unwanted side reactions.  
 Obtaining the lactone starting material, 31, was planned as the first step 
with halogen substitution alpha to the nitro group (Figure 8, C2). The synthesis of 
these inhibitors utilized a Henry reaction with 2-formylbenzoic acid (2-FA) and 
nitromethane. This reaction is very similar to an aldol reaction in which a proton 
attached to the same carbon with an electron-withdrawing group is removed by 
base; the resulting carbanion reacts with the carbonyl carbon of an aldehyde. 2-
FA has been investigated in a variety of reactions for its ability to react in fairly 
mild conditions.
69, 70
 By starting from 2-FA and nitromethane, 31 forms readily 
and is isolated in high yields from an alkaline solution of aqueous alcohol. 
Scheme 12. Synthesis of 32 
 
Substitution of the aromatic ring with iodine was also desired for this 
structure in order to make future analogues easier to substitute on the aromatic 
ring. Substitution of iodine starting from 2-FA was attempted but not very useful. 
Adding it to an iodinating solution resulted in the recovery of 2-FA along with 
many products that formed in small amounts. Ring closure of 2-FA in acetic acid 
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provided the acetate protected lactol,
69
 which was subjected to the electrophilic-
iodine reagent. Unfortunately, the acetate was removed in situ, and it provided 
many products along with 2-FA. The two dibrominated nitrolactones products, 33 
and 35, which are described later, were also individually subjected to the 
iodinating solution with minimal isolation of any iodoaryl products.  
The procedure used to acquire acceptable yields of C7 (Figure 8) iodine 
substitution required addition of 31 to the electrophilic-iodine reagent (Scheme 
12). Recovery of the desired C7 iodine product from solution was possible despite 
C9 substitution and formation of other minor products. All crude products also 
contained the reactant, 31. A good amount of the C7-substituted product was 
obtained by precipitation when chlorinated solvent was added to the crude 
reaction product; it did co-precipitate with 31, however. Both 31 and 32 spots do 
not separate greatly on TLC, and they could not be separated very easily with just 
column chromatography. Recrystallization from chloroform and hexanes or ethyl 
acetate and hexanes, however, effectively separated the iodide-substituted 
product. 
2.7 Synthesis of Dibrominated Nitro Lactones 
No suitable references were found that specified how to individually 
substitute a hydrogen alpha to a nitro group except under special or extreme 
conditions. Some methods require the organic nitro compound to be soluble in 
one equivalent of an alkaline solution while cold, typically –20 to 0 ºC.71,72 This 
requires the organic compound to be soluble in a small or reasonably small 
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amount of the alkaline solution, which is not the case for 31. Furthermore, some 
literature techniques, e.g., Wohl-Ziegler reaction, that were used successfully to 
monobrominate alpha to a carbonyl group did not work with the nitro group.
73, 74
  
Regardless, dibromo substitution of the nitrolactone on C2 (Figure 8) was 
relatively simple by use of a biphasic reaction mixture and bromine (Scheme 13). 
This procedure did take 2 or more days to complete in good yields, however. It 
was thought that 31 initially dissolved in DCM and would deprotonate to open the 
lactone ring in slightly alkaline aqueous solution; the ionic intermediate would 
preferentially dissolve in the aqueous solution. If an electrophile is present, such 
as bromine, then the reversible ring closure would result in competitive reaction 
between proton and bromine. After two bromine atoms attach to C2 however, the 
new product would remain in the organic phase. While bromine is very soluble in 
DCM, it is somewhat soluble in aqueous solution, too.  
Scheme 13. Synthesis of 33 
 
The reaction mixture was monitored by TLC, and it showed a minor spot 
had appeared between those of 31 and 33, when only one molar equivalent of 
bromine was present. This implied that the intermediate product, i.e. a single 
substitution of bromine at C2, favored reaction with bromine a second time, over 
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monobromination of 31. In other words, the initial bromination is likely to be the 
rate-limiting step. 
The biphasic reaction used to make 33 was not effective when 32 was the 
starting material. Also, it did not dissolve in DCM to the same extent as 31. When 
the reaction was allowed to stir over long periods, it did appear to dissolve, but 
very low yields of 34 were isolated. Several organic bases (including pyridine, 
triethylamine and 2,6-lutidine) were used exclusively in organic solvents instead 
of biphasic reaction mixtures. Along with NBS and Br2(l), another brominating 
agent, pyridinium bromide perbromide (pBpB), was used as the source of 
bromine.
75
 A reaction system with 32 and 2 equivalents each of pBpB and 2,6-
lutidine in THF resulted in high yields of 34 (Scheme 14). 
Scheme 14. Synthesis of 34 
 
When only one equivalent of each reactant was added, the reaction was 
incomplete, as 32 and 34 were mainly recovered, i.e. single bromine substitution 
on C2 was also not favored in this system. Typically, one equivalent of base and 
pBpB were allowed to react until the reaction solution's red color had faded. At 
this point, the second equivalent of each was added. This same system was used 
on 31 to form 33 as well. 
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2.8 Synthesis of Monobrominated Nitro Lactones 
Scheme 15. Synthesis of 35 
 
Because 33 was easy to make and isolate in the biphasic reaction, this 
product was acquired, and a synthesis to replace a single bromine with hydrogen 
was attempted. A couple of methods were found that could replace one of the 
bromines with hydrogen from readily available reagents. One method could not 
be tested sufficiently, though, as the lab reagent stannous chloride dihydrate was 
not sufficiently pure.
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 However, a reactant with very similar functional groups 
and characteristics as 33 had been found to be reduced with thiourea in an 
aqueous acetic acid solution.
77
 When 33 was subjected to the same procedure 
(Scheme 15), a precipitate formed during the course of the reaction in very high 
yield and in large excess of one diastereomer. 
For this reaction, 33 was first dissolved in acetic acid, and thiourea was 
separately dissolved in the same volume of water. The aqueous thiourea had to be 
slowly added to cause the desired precipitation in which one diastereomer formed 
and precipitated substantially from the solution. If the aqueous solution was added 
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in one portion, immediate formation of a precipitate resulted, as a lightly yellow 
colored solid, but it rapidly redissolved into solution. It is not known if this initial 
precipitate was 33 crashing out of the reaction mixture, or the desired product. 
However, precipitate formed after the solution was stirred for a few minutes, but 
the solid was darker yellow than the pale yellow solid obtained with slow addition 
of aqueous thiourea. Furthermore, this solid contained a larger proportion of 36, 
the diastereomer of 35, as evidenced by the increased intensity of doublets 
coupled with J = 7.5 Hz (Figure 13). 
The TLC spot of 35 appeared at lower Rf than 33, and another spot 
appeared at lower Rf still when excess thiourea was used (DCM developing 
solvent). The lowest spot appeared because of a double replacement of bromine 
with hydrogen to form 31. The precipitated solid product was preferentially 
purified, in good yields, by immediate recrystallization from ethyl acetate and 
hexanes. The hydrogen on C2 is too labile when silica gel chromatography was 
attempted, and 35 could not be separated from 36. The diastereomers 35 and 36 
were recovered as a mixture in nearly equal quantities because of reversible 
deprotonation while moving through the column. 
Scheme 16. Synthesis of 37 
 
50 
A small amount of the isolated 34 was briefly subjected to the same 
conditions described in Scheme 15. Unfortunately, 34 is only slightly soluble in 
acetic acid. The reaction was still attempted with what was soluble, however. 
Initially, the reaction seemed to proceed as expected, with some precipitate 
developing, but more precipitate formed that was orange to orange-red in color 
over time. Dissolving this precipitate after filtration was nearly impossible. A 
silica gel column was run to help separate any useful compounds from the 
insoluble orange-red material. However, 34 was recovered from the column, and 
very little of anything else. Small amounts of orange-red precipitate would form 
periodically from the original reaction filtrate (aqueous and acetic acid solution) 
left to stand. The orange-red precipitate was insoluble in many organic solvents. 
This material may be polymeric, but it is not clear how. 
A change in solvent system was tried (Experimental, Table 8) from what 
had worked with 33. While acetic acid was used in a few trials, it was replaced 
with another organic solvent that could completely dissolve 34. An aqueous acid 
was used to replace the organic acid, too. Tetrahydrofuran (THF) was used since 
it is miscible with water, and 34 is soluble in it. Aqueous hydrochloric acid was 
also chosen as the acid replacement in most tests. Interestingly, initial tests 
revealed an incomplete reaction by TLC when only one equivalent of thiourea 
was used. Reactions with 33 showed evidence for replacement of both bromines 
when excess thiourea was used, and the referenced paper reports a similar double 
replacement with two equivalents of thiourea.
77
 Thus, two equivalents of thiourea 
had to be used to effect the desired hydrogen substitution of a single bromine. 
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Slightly more than two thiourea equivalents did not cause two bromines to be 
replaced to any noticeable extent either, by TLC. This reaction system was varied 
to the point in which one diastereomer was slightly favored, but multiple 
recrystallizations were required to completely isolate 37 from its diastereomer. 
2.9 Henry Reaction with Bromonitromethane and 2-Formylbenzoic acid 
Scheme 17. Synthesis of Crude 36 by the Henry Reaction 
 
 A separate Henry reaction was attempted with bromonitromethane. 
Nitromethane could be brominated once to bromonitromethane in high yields if 
done carefully and quickly.
71
 As mentioned earlier, addition a single bromine 
alpha to a nitro group is possible and has been documented in cases of aqueous-
soluble organics. The cited patent procedure was found to be very effective.
72
 The 
desired bromonitromethane accounted for more than 80% of the product by 
1
H 
NMR, with nitromethane and dibromonitromethane accounting for the rest in 
decreasing amounts (Experimental, Table 9). Distillation was only attempted one 
time to further purify the material, but the high boiling point and small amounts 
prepared resulted in low recovery with limited increase in purity (by NMR).  
The Henry reaction with bromonitromethane utilized a procedure similar 
to one found in a patent too.
78
 Methylamine and sodium carbonate were used in 
0.1 equivalents to an aldehyde on a furan ring in the patented procedure. 
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However, one equivalent of sodium bicarbonate was included in the following 
procedure, unlike the patent. The first reaction in which this slightly amended 
procedure was employed led to recovery of a precipitate containing 2 products in 
~ 1:6 ratio and a 42% yield based on formation of 35 or its isomer. The minor 
product, however, only showed peaks in the aromatic region of the 
1
H NMR 
(Figure 11). 
 
 
Figure 11. First Henry reaction with 2-FA and bromonitromethane. Impurity 
peaks are circled. Other peaks are from compound 36 with the doublet peaks, on 
the right, J = 7.5 Hz. 
 
One of its most noticeable peaks is a doublet near δ 8.4 ppm, while a triplet also 
appears around δ 7.9 ppm. Other peaks for the minor product are expected to be in 
the aromatic region, but they are being overlapped by the major product 36. The 
doublets around δ 6.0 and 6.1 ppm (J = 7.5 Hz for both) are attributed to the 
desired bromo lactone product 36. 
 The unknown minor product, which has the furthest downfield doublet, 
could be from the reaction involving 2-FA and the small amount of 
dibromonitromethane present in the prepared bromonitromethane liquid (Figure 
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12). Formation of 33 is probably not the favored pathway to the boxed product, 
but a tiny peak in the above crude spectrum at δ 6.4 ppm may be a singlet. This is 
the typical location of the only non-aromatic hydrogen of 33. 
 
 
Figure 12. Possible pathway to unknown product, BNLA, the product proposed 
to be responsible for the doublet at δ 8.4 ppm appearing in Figure 11. 
 
 The major product in this precipitate had essentially only one set of 
doublets between δ 6.2 to 6.0 ppm (J = 7.5 Hz). Synthesis of 35, from 33 and 
thiourea, also favored one product with a specific set of coupled doublets (J = 3.6 
Hz, Figure 13). However, the diastereomer of 35 formed more favorably under 
the Henry reaction conditions based on the coupling of the doublets (Figure 13). 
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Figure 13. Comparison of doublets for 35 and its diastereomer 36. 
1
H NMR of 
doublets for 35 (bottom) and 36 (top), expanded on δ 6.7 to 5.7 ppm. 
 
 The low yield from this and subsequent reactions is probably from the 
reaction of water with intermediate products or with the minor product that was 
boxed in Figure 11. Additional discussion about this possible product and 
transformations can be found in Chapter 3.7 (see Figure 43). 
 
 
Figure 14. Pathway resulting in lost product from 2-FA reaction with 
bromonitromethane. Symmetric aromatic protons would appear from a phthalate 
analogue. 
 
The solvents used in the initial reaction, water and ethanol, would likely 
keep the phthalic acid dissolved even upon acidification of the solution. If 
phthalic anhydride formed as an intermediate product, then it could also react 
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with bromonitromethane, as reactions with nitromethane are known, although 
they occur under more forceful conditions (Figure 15).
79
 This is another pathway 
to the crude product seen in the spectrum as the furthest downfield doublet at ~ 
8.4 ppm. Unfortunately, only the first reaction using the procedure in Scheme 17 
resulted in large amounts of precipitate during the workup. Several 
1
H NMR 
spectra of crude products from subsequent reactions showed evidence of the lactol 
forming as well as the ethanol substituted lactol.
80
 
 
 
 
Figure 15. Phthalic anhydride pathway to BNLA product. 
Attempts at a monobromination reaction starting from 31 of with N-
bromosuccinimide [NBS] employed two different procedures. The first was just 
by heating in chlorinated solvent (both in the dark and in light), and the second 
method utilized peroxides (t-butyl hydroperoxide) in an attempted radical 
reaction.
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 Heating with NBS in both the dark and light provided only 33, but it 
was difficult to isolate in good yields, as an equilibrium seemed to form with the 
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starting material. Using peroxides did not cause any change except for some 
possible dibromination occuring in low yields. 
One reaction mixture was allowed to stand for several days in a biphasic 
mixture of water and DCM with added bromine. After most of the DCM 
evaporated, solid crystals formed in the remaining aqueous solution. Collection of 
the crystals and analysis by TLC showed the appearance of an additional spot at 
much higher Rf than the starting material 31 and slightly higher than 33. A 
1
H 
NMR spectrum indicated bromine substituted for the benzyl hydrogen, on C3 
(Figure 8). This results in doublets appearing between δ 5.52 and 5.35 ppm (J = 
14.4 Hz, Figure 16). A modification of the procedure, with either NBS or bromine 
in quartz tubes and chlorinated solvents only, did not provide the desired products 
(35 or 36). 
 
Figure 16. Bromination at C3 instead of C2 of 31. Crude mixture of 31 (C2 and 
C3 protons in boxes) and the suspected bromo-substituted product on C3 (geminal 
protons on C2, J = 14.5 Hz, circled). 
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3 RESULTS AND DISCUSSION 
3.1 Cancer Cell Line Assay Background 
 The first analysis done on the inhibitors was a growth inhibition assay 
with three to six cancer cell lines. An absorbance measurement from either the 
sulphorhodamine B (SRB, Figure 17) or methylthiazolyldiphenyl-tetrazolium 
bromide (MTT, Figure 18) assay determined the effectiveness of an inhibitor. 
Cytostatic cell data are collected as an IC50 (or GI50), which is the concentration 
of a compound that results in a 50% reduction of the net protein increase, and 
total growth inhibition (TGI), which is the concentration resulting in zero net 
protein increase. Cytotoxic data are collected as the LC50, which is the 
concentration of compound that would result in a 50% reduction of the measured 
protein at the end of drug treatment when compared to the beginning. All values 
are compared to cell growth when no inhibitor is present. 
 The SRB and MTT assays provide comparable results when limited to 
IC50 data.
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 The SRB assay can provide additional data like TGI and LC50 that are 
not available with the MTT assay. The SRB assay utilizes a pink, negatively 
charged aminoxanthine dye. This is a protein-staining dye that binds to basic 
amino acids inside cells. The assay is run in a multi-well plate in which cells are 
allowed to grow in the presence or absence of an inhibitor. After fixing viable 
cells to the plate, the dye is added and taken up by the cells. Then the cells are 
lysed, and the absorbance is measured between 490–530 nm to determine the 
amount of dye that was taken into the cells.
82
 The optical density of SRB is 
proportional to the cell number. A plot of optical density against inhibitor 
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concentration allows the IC50 (or GI50) to be determined. Furthermore, this is the 
standard assay method used by the NCI in their 60-cell-line screen, and they 
provide simple equations to calculate the inhibition concentrations for the GI50, 
TGI and LC50.
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Figure 17. Sulphorhodamine B structure. 
 Unlike the SRB staining assay, the MTT assay relies upon a cellular 
conversion to an optically measurable product. Furthermore, the formazan 
product that forms is not soluble in the assay solution. Thus, an additional 
solubilizing step must be performed prior to measuring the optical density. The 
tetrazolium bromide is reduced in the mitochondria of a cell by intracellular 
NAD(P)H oxidoreductases during the cell growth period. This assay only 
provides GI50 data since it relies on viable cells to produce the optically detectable 
formazan. 
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Figure 18. Methylthiazolyldiphenyl-tetrazolium bromide conversion to thiazolyl 
blue formazan. 
 
3.2 Cancer Cell Growth Inhibition Results for Cinnamic Acid Analogues 
The first set of compounds synthesized were the halogenated diesters of 2-
carboxycinnamic acid (2-CCA). While the diacid form of the compounds would 
mimic the 2-(oxalylamino)-benzoic acid (OBA) more accurately, the diester form 
should enter cells better, whereupon esterases would liberate the corresponding 
acids. Furthermore, the reported OBA analogues are described in enzyme 
inhibition assays and not whole-cell assays.
34, 42
 Unfortunately, this set of diester 
compounds did not significantly inhibit the cancer cell growth. Compound 4 did 
have a GI50 of 4.2 µM against the breast cancer cell line MCF-7. However, this 
was the only compound and cell line with a GI50 below 10 µM (Table 2). In 
general, the bromo compounds had greater inhibition than analogous chloro 
compounds. Both of the chloro compounds, 2 and 3, showed relatively high GI50 
values, and no measurable TGI or LC50 could be determined. In almost every 
case, the dihalogenated compound outperformed its corresponding 
dehydrohalogenated Michael-acceptor (i.e. 2 vs 3 and 4 vs 5). 
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Table 2. Human Cancer Cell Line Growth Inhibition (SRB Assay) for 2–5; values 
in µM 
 
Compound 
 
BXPC-3 MCF-7 SF-268 NCI-H460 KM20L2 DU-145 
2  
(343) 
GI50 
TGI 
LC50  
110 
ND 
ND 
105 
ND 
ND 
122 
ND 
ND 
110 
ND 
ND 
134 
ND 
ND 
125 
ND 
ND 
3  
(392) 
GI50 
TGI 
LC50 
127 
ND 
ND 
179 
ND 
ND 
155 
ND 
ND 
126 
ND 
ND 
182 
ND 
ND 
156 
ND 
ND 
4  
(263) 
GI50 
TGI 
LC50 
41.6 
80.8 
157 
4.2 
38.7 
124 
46.3 
85.3 
157 
51.3 
122 
ND 
29.7 
68.4 
157 
36.6 
79.5 
173 
5 
 (334) 
GI50 
TGI 
LC50 
65.9 
129 
254 
102 
290 
ND 
64.9 
139 
298 
56.5 
132 
310 
110 
ND 
ND 
44.5 
186 
ND 
BXPC-3 (pancreas adenocarcinoma), MCF-7 (breast adenocarcinoma), SF-268 
(CNS glioblastoma), NCI-H460 (lung large cell), KM20L2 (colon 
adenocarcinoma), DU-145 (prostate carcinoma). The assay was carried out with a 
maximum dose of 100 µg/mL for each compound. 
ND: No Detection of inhibition at the highest concentration tested as shown in 
micromolarity in parentheses below the compound number. 
 
The X-ray structure of 3 was solved after the SRB assay and subsequent 
PTP assays were complete (Figure 19). The π orbitals of aryl carboxylic ester and 
the phenyl ring were essentially coplanar.
61
 This forced the chloropropenoate 
chain out of planarity with the benzene ring. The pi-orbital interaction between 
the phenyl ring and the propenoate will not be as strong as it would if planarity 
were intact. Without this extended conjugation, the beta carbon should be more 
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electrophilic, and hence, more capable of binding to a nucleophilic cysteine. 
However, this low-energy alignment appears to have had no effect on its capacity 
to inhibit cell growth. 
 
Figure 19. X-ray structure of 3; the propenoate group is at an angle of 133.53° 
with the benzene ring (C2-C1-C7-C8).
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The ring closures of halogenated cinnamic acids resulted in halogenated 
lactones. The iodo lactone 26 was submitted for testing prior to the maximum 
dosage in SRB assays being reduced from 100 µg/mL to 10 µg/mL. 
Unfortunately, the two chloro lactones 11 and 12 were submitted and analyzed at 
the lower maximum dosage, and none of the inhibition parameters were below the 
maximum concentration employed in the assay. Since the chlorinated lactones are 
diastereomers, they both share a maximum testing concentration of 41.6 µM, 
which is far below the best cell-inhibition concentration for 26 (Table 3). The 
dosage change prevented a more complete comparison of these three compounds 
to each other. Furthermore, all subsequent SRB data were collected at the new, 
lower dosage. 
 
 
62 
Table 3. Human Cancer Cell Line Growth Inhibition (SRB Assay) for 26; values 
in µM 
 
Compound  BXPC-3 MCF-7 SF-268 NCI-H460 KM20L2 DU-145 
26 
(218) 
GI50 
TGI 
LC50  
94.5 
ND 
ND 
73.4 
ND 
ND 
71.0 
ND 
ND 
88.6 
ND 
ND 
ND 
ND 
ND 
97.2 
ND 
ND 
BXPC-3 (pancreas adenocarcinoma), MCF-7 (breast adenocarcinoma), SF-268 
(CNS glioblastoma), NCI-H460 (lung large cell), KM20L2 (colon 
adenocarcinoma), DU-145 (prostate carcinoma). The assay was carried out with a 
maximum dose of 100 µg/mL for each compound. 
ND: No Detection of inhibition at the highest concentration tested as shown in 
micromolarity in parenthesis below the compound number. Diastereomers 11 and 
12 were tested at ≤ 41.6 µM and no inhibition parameters could be determined. 
 
 For a brief period, the MTT assay was used in place of the SRB assay. A 
couple of cell lines were removed during the MTT assay period, but the 100 
μg/mL dose was used in this assay for every compound against each cell line. 
Since the iodo-substituted aromatic compounds and lactone alkenes had been 
made at the time of the switch, they were subjected to the MTT assay (Table 4). 
While similar GI50 data can be expected between the two assays,
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 comparing 
potential inhibitors with differing assays and cell lines is not ideal. The MCF-7 
and DU-145 cell lines were used in both assays, except for when compound 23 
was submitted (Table 4). However, the MTT assay did include a nontumorigenic 
(but immortalized) breast cell line, MCF-10A, which acts as an initial test for 
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toxicity against normal cells. This may help determine if an inhibitor can 
effectively target a cancer cell line over a normal one, or suggest the extent to 
which a normal cell line would be harmed. 
Table 4. Human Cancer Cell Line Growth Inhibition (MTT assay) results for 23, 
24, 27, 28 and 29; GI50 values in µM 
 
Compound MCF-7 MCF-10A A549 3LL
a
 or DU-145 
23 (197)
a
 ND 76.5 ND ND 
24 (248) ND 18.9 21.1 19.9 
27 (301) ND 11.1 ND ND 
28 (301) ND ND ND ND 
29 (218) 19.0 4.6 9.4 10.3 
MCF-7 (breast adenocarcinoma), MCF-10A (non-tumor breast epithelial), A549 
(lung adenocarcinoma), 3LL (Lewis lung carcinoma), DU-145 (prostate 
carcinoma). 
The assay measured a maximum dose of 100 µg/mL, and the concentration 
corresponding to that dose for each compound is displayed in parentheses. 
ND: No Detection of inhibition at the highest concentration tested as shown in 
micromolarity in parentheses next to the compound number. 
a
 23 was the only compound assayed with the 3LL cell line, and all others were 
assayed against the DU-145 cell line. 
 
Compounds 23 and 24 are analogous, differing only in the type of halogen 
substitution. The dibromo compound 23 was not active against any of the tested 
cancer cell lines, while the dichloro analogue 24 did show some activity. Since 
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the GI50 can be compared between the MTT and SRB assays, the diester 
analogues 2 and 4 can be compared to ring-iodo monoesters 23 and 24 via the 
MCF-7 cell line. Notably, 23 does not inhibit MCF-7 cell growth, while the 
diester analogue 4 had micromolar activity (Table 2). 
The aryl iodo substituent may have hindered the entry of 23 into the cells, 
or it was indiscriminately active prior to or after entry. The activity against the 
non-tumorigenic breast cell line, MCF-10A, make it appear as though 23 was 
entering cells during the assay period, however. If it was entering cancer cells too, 
then it was likely too reactive and not capable of reaching a vital enzyme or 
cellular component of the mutated cells. Neither 23 nor 24 were active against the 
breast cancer cell line, MCF-7, but they both inhibited the growth of MCF-10A. 
Compound 24 was active against the lung and prostate cancer cell lines, while 23 
was not active against two separate lung cancer cell lines (A549 and 3LL). The 
SRB assay used a different lung cell line, NCI-H460, for inhibition data collected 
with 4. Even though this is not the same cell line as either of those tested in the 
MTT assay, the lack of any inhibition against two lung cell lines for 23 was still 
unexpected. This was even more unexpected since 24 did inhibit A549, the lung 
cell line tested for both of these compounds. 
Since other halogenated lactones, 11, 12 and 26, had limited or no 
observable activity from SRB assays, it is conceivable that 23 readily cyclized 
into a halogenated lactone, with loss of HBr, during the MTT assay period (Figure 
20, 23a). In general, bromide is a better leaving group than chloride, and 23 could 
favor lactone formation, whereas the dichloro analogue 24 may not. If HBr is 
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eliminated and the lactone forms, then the activity of 23 may be similar to the 
corresponding iodo lactone 26. Cell-free experiments to open the lactone of 26 
were unsuccessful, and the same would be expected for the bromo lactone. 
 
Figure 20. Possible formation of a bromo lactone 23a. A reactive halogenated 
olefin 23b is not expected to form in situ during the assay. Elimination of HBr 
(from C2 and C3 respectively) may precede lactone formation, or loss of H from 
the carboxylic acid with Br (from C3) may occur directly. 
 
 NMR and a preliminary X-ray analysis confirmed that hydrogen iodide 
had been eliminated from 26 to form the previously unreported 29. The cis-trans 
isomers, 27 and 28, were also obtained by elimination of HI from 25 and are 
known compounds.
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 The aromatic-iodine substitutent had a great effect on the 
inhibitory activity of this structure.  
 Despite the deviation from halogenated alkyl and alkenyl groups, the data 
collected on 29 provided a possible in vitro transformation to explain the limited 
cell-growth inhibition activity for 26. This compound was not very active (Table 
3), but its limited activity may come from in situ hydrogen-iodide elimination to 
form 29. If the halogenated lactone compounds require dehydrohalogenation to 
become active, then 11 and 12 would eliminate HCl and produce 27 and/or 28, 
which were both inactive in the MTT assay. If 23 forms 23a (Figure 20) and HBr 
is subsequently eliminated, then the structure would match 29 or the untested 
isomer 30. The activity of 23 would then be comparable to 29, but it is not. This 
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can be explained by noting the limited activity of the iodo lactone, 26. 
Elimination of HI to make 29 provided some growth inhibition data (Table 3). 
Since iodide is usually a better leaving group than bromide, 26 would be expected 
to form 29 more readily than 23 would form 23a. A similar bromo lactone would 
eliminate HBr more slowly and not inhibit cell growth. For synthesis of an 
analogous bromo lactone and subsequent HBr elimination see, Elvidge, et al.
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 The formation of the 23a is hypothetical. It would not be expected to form 
and subsequently undergo dehydrobromination in assay buffer very easily. 
Therefore, it is not likely to produce 29. A mechanism-based activation of the 
bromo lactone compound by an enzyme (or other cellular component) could 
produce the brominated Michael-acceptor (Figure 20, 23b), but this does not seem 
to have occurred. The chloro analogue 24 may not favor forming a lactone at all, 
as chloride displacement would be required in situ. Chloride is generally a poorer 
leaving group in comparison to bromide. It is far more likely to inhibit cell growth 
without transforming into a chloro-lactone (i.e. 11 or 12) or alkene like 29.  
3.3 Protein Tyrosine Phosphatase Assay with Analogues of Cinnamic Acid and 
para-Nitrophenyl Phosphate 
 
Figure 21. Dephosphorylation of pNPP to pNP by a tyrosine phosphatase. The 
nitrophenolate product absorbs around 405 nm. 
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 The first PTP assay used was a colorimetric assay that measured para-
nitrophenyl phosphate (pNPP) conversion to para-nitrophenolate (pNP) by 
absorbance at 405 nm (Figure 21).
40,84,85
 The pH of the assay buffer was between 
7.0–7.4 as specified by the enzyme manufacturer (see Experimental), but several 
PTPs have been reported to display higher activity at lower pH.
44
 
 Several compounds (Figure 22) were used in this assay with an already 
described buffer.
40
 They were individually dissolved in DMSO before being 
screened. The compounds were added to an enzyme in aqueous buffer (< 5% 
DMSO) and pre-incubated for 20–60 minutes. The reaction was started by 
addition pNPP and terminated by addition of a hydroxide solution after two or 
three minutes. The absorbance measurement was recorded at 405 nm, and a 
comparison was made between the compound wells and control wells (DMSO 
without a test compound dissolved into it). Regardless of the concentration used 
against PTP1B and PTPβ, none of the compounds (Figure 22) inhibited the 
activity of either enzyme. 
 Precipitation of some compounds from the assay buffer prevented testing 
at high concentrations, e.g., ≥ 100 µM. The DMSO-stock solutions of compounds 
were diluted into assay-buffer stock to their highest, visibly soluble concentration 
(see Experimental). These new stock solutions of the compounds were used in 
assays, but the enzymes were not inhibited. A known inhibitor of PTPases, 
sodium orthovanadate, was used during some assays, and enzyme activity was 
inhibited when it was used.
86 
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Figure 22. Compounds assayed against PTP1B and PTPβ with pNPP. 
 
3.4 NMR Experiments with Alkenyl Analogues of Cinnamic Acid and Thiols 
After several assay attempts with pNPP failed to show inhibition of the 
two PTP enzymes, a possible deactivating reaction between dithiotreitol (DTT) in 
the assay buffer and the compounds was considered. Two compounds were 
analyzed in NMR experiments for their ability to add a thiol. Compound 3 was 
separately run with DTT and N-acetylcysteamine (NAC), whereas 29 was studied 
with NAC only. 
A mixture of 3 and DTT (1:1) in CDCl3 was prepared, but there was no 
evidence of a reaction between the two. Since the enzyme assay is conducted 
between pH 7.0 and 7.4 with a pre-incubation step, a thiolate may be generated 
from DTT while in the assay buffer. Furthermore, DTT was present in millimolar 
concentrations, while inhibitors were in micromolar concentrations (i.e., between 
100:1 and 1000:1 of DTT:3). Therefore, even a small amount of thiol-to-thiolate 
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conversion of DTT could result in reaction with an available electrophile. After an 
equivalent amount of DBU was added to the NMR tube with 3 and DTT, new 
peaks appeared in the aromatic region between δ 7.9 to 7.3 ppm (Figure 23). 
These new peaks are a clear indication of reaction of the thiolate of DTT with 3. 
Figure 23. Observed NMR spectrum of 3 and DTT. Spectra are shown with (top) 
and without (bottom) DBU, between about δ 9–4 ppm in CDCl3. 
 
 New peaks also appeared between δ 5.6 ppm and 4.8 ppm (Figure 23). 
Upon addition to the carbon-carbon double bond of 3 (Figure 24), this would be 
the expected location for the propanoate hydrogens. However, the splitting for 
these peaks is complex, and this is likely from more than one product being 
generated. The peaks around δ 4.8 ppm appear to be a large doublet of doublets 
partially overlapping a smaller doublet of doublets, while the peaks around δ 5.6 
ppm appear to be a large doublet overlapping what may be a smaller triplet. 
 After this NMR reaction mixture was stored in the dark at about 4 °C for 
about one month, another spectrum was acquired. Several broad peaks still 
appeared in the region for aromatic protons and in the region between δ 6.5 ppm 
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to 4.8 ppm. One very distinct set of peaks separated from, or rose above, the 
noise. These appeared to be from an analogue of 2-CCA. Two doublets with 
equivalent integration appeared at δ 8.4 ppm and δ 6.3 ppm (J = 16 Hz). 
Additionally, a few peaks within the aromatic region separated from the other 
broad peaks, and they integrated equivalently with these doublets. The two 
coupling constants of 16 Hz and doublet locations of δ 8.4 ppm and δ 6.3 ppm are 
typical for the olefin protons of a structure like 2-CCA. Therefore, a hydrogen 
substitution of chloride occurred. If the initial Michael addition by the thiolate of 
DTT occurred as proposed, then this 2-CCA analogue could have arisen from an 
intramolecular disulfide formation with subsequent chloride elimination (Figure 
24). 
 
Figure 24. Thiolate of DTT reaction with 3. Disulfide bond formed with 
expulsion of chloride to generate the olefin. 
 
 A different thiol, NAC, was used to investigation thiolate reaction and 
episulfonium ion formation. This thiol is a closer model for cysteine than DTT, 
and there is no possibility of intramolecular disulfide formation. Addition of the 
thiolate generated from NAC, proceeding to episulfonium ion, and elimination of 
HCl would generate a new product (Figure 25). 
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Figure 25. Thiol reaction with 3 and possible episulfonium pathway to a distinct 
product. Two potential routes to a new product are available. One of these 
products would provide preliminary evidence of an intermediate episulfonium ion 
formation (bottom right).  
R, -CH2CH2NHC(O)CH3 
 
 
 Similar to the DTT experiment, there was no reaction with 3 prior to the 
addition of DBU (Figure 26, bottom). New aromatic peaks appeared along with 
doublets between δ 5.7 to 4.7 ppm after DBU was added. 
Figure 26. N-Acetylcysteamine NMR experiment with 3. Equivalent amounts of 
3 and NAC (bottom); 5 minutes after an equivalent amount of DBU was added 
(middle); 32 minutes after DBU addition (top). The solvent is CDCl3. 
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Only one product may have formed based on the top two spectra in Figure 26. 
While broad peaks are seen near the doublets between δ 5.7 ppm to 4.7 ppm, there 
does not appear to be new aromatic or ester peaks that correlate with them. In 
addition to the two methyl ester singlets for 3, there are three developing methyl 
ester singlets and not two, as may be expected from a single reaction product. 
However, two of these peaks (peaks 4 and 5, Figure 27) sum to the same value as 
the other, new singlet (peak 1, Figure 27). 
 
Figure 27. New methyl ester peaks from NAC and 3 reaction. Methyl esters for 3 
(bottom), 3 + NAC + DBU after 5 minutes (middle), and again after 32 minutes 
(top) from Figure 26. The sum of the peaks labeled 4 and 5 integrate to the same 
value as peak 1. 
 
The singlet peak labeled 1 is due to the phenyl ester, and the other peaks likely 
arise from an equilibrium between an intermediate carbanion and subsequent 
protonation (Figure 28). 
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Figure 28. Proposed addition of NAC to 3. The thiolate from NAC was generated 
after a reaction with DBU, and its proposed addition to 3, based on 
1
H NMR 
observation, is shown. 
 
This NMR reaction mixture was stored in the dark at about 4 °C for 13 
days, and another spectrum was acquired. Essentially only 3 was found and no 
addition products. A very small singlet was seen just to the right of the olefinic 
proton singlet from 3 (C2, Figure 8), along with some small aromatic peaks. 
There are small singlets near 3.7 ppm, but the most abundant one integrates to  
< 10% of the methyl ester singlets for 3. The doublet peaks and N-H peak from 
NAC between δ 7.0 ppm to 4.7 ppm are no longer present either. There are two 
triplets at δ 3.54 ppm and 2.84 ppm and a singlet at δ 2.02 ppm that integrate to a 
2:2:3 ratio. In addition to the missing N-H broad peak, the triplet peak that would 
be expected from the thiol proton at δ 1.35 ppm is no longer present. These 
observations indicate an intramolecular reaction of NAC to form 2-methyl-2-
thiazoline (Figure 29). The locations of these new peaks differ slightly from what 
has been described in the literature,
87, 88
 but that may be caused by the presence of 
DBU and water coming from dehydration of NAC. However, the NMR mixture 
was not separated or analyzed further to confirm the cyclization. 
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Figure 29. DBU proposed dehydration of NAC to 2-methyl-2-thiazoline. 
 
 The thiolate of NAC was undergoing an intramolecular cyclization and 
reacting with 3. After 13 days, NAC may have generated 2-methyl-2-thiazoline. 
The initial interaction observed by NMR (Figure 26) was likely an association-
disassociation equilibrium between the two. Formation of 2-methyl-2-thiazoline 
seems to be favored over the desired addition-to-episulfonium conversion that 
would form a new product from 3. 
After positive MTT assay results, 29 was subjected to a similar NMR 
experiment. If a nucleophile is added to the alkene bond, then it is possible for the 
double bond to isomerize to the Z-alkene upon elimination of said nucleophile. 
Addition of a nucleophile is the only step expected for this substance. If thiolate 
does add, future syntheses could be devised with the olefinic proton substituted by 
a halogen. Such a change would allow for an episulfonium ion to be generated. 
 The two spectra (Figure 30) show the starting material 29 and its Z-isomer 
30 that was isolated with some minor impurities during synthesis. A spectrum 
with peaks matching the E- and Z-isomers 29 and 30 would be generated if NAC 
is added and eliminated from 29. An NMR spectrum of just 29 and N-
acetylcysteamine showed no addition had occurred. This is similar to NMR 
experiments with 3, as these structures are not electrophilic enough to induce a 
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nucleophilic attack by thiol. Both require a base to generate the more nucleophilic 
thiolate. 
 
Figure 30. Spectra of 29 and its slightly impure Z-isomer 30 (top, in CDCl3 and 
bottom, in acetone-d6 respectively), are shown from δ 9 to 6 ppm. There is a 
distinct downfield shift of the aromatic doublet for 29, top, which is due to the 
ester carbonyl anisotropy.
64, 65
 
 
Figure 31. NMR spectra comparison for thiol reaction with 29. Spectra of 29 
(bottom, in CDCl3), 30 (middle, in acetone-d6) and the reaction mixture of NAC 
with 29 (top, in CDCl3). A second NMR spectrum of the reaction mixture was 
acquired several minutes later, but it was identical to the one displayed at the top. 
 
 Several new peaks were found in the spectrum after DBU was added 
(Figure 31, top). Since DBU and NAC do not have aromatic protons, only 
reaction intermediates and products derived from 29 could produce the new 
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peaks. TLC of the NMR solution showed two noticeable spots, and a short silica 
gel column separated the materials responsible. This resulted in recovery of 29 as 
the high running spot, contaminated with a small amount of 30 and another 
unknown product (Figure 32). The small amount of contamination by 30 is 
readily apparent by the aromatic peaks, but the most notable peak is a second 
olefinic proton singlet near δ 5.8 ppm, which is just upfield of 29's olefinic proton 
singlet. The unknown impurity also has aromatic signals. Three singlets formed 
between δ 8.3 to 8.1 ppm (two of which come from 29 and 30), and this would 
imply the unknown contains the aromatic ring. A previously unseen doublet has 
appeared just to the left of a known doublet for 30 at δ 7.4 ppm. Another peak is 
partially over lapped around δ 8.1 ppm too.  
 
Figure 32. High spot column separated NMR reaction of thiol and 29. NMR 
spectra of 29 (bottom) and high spot column separated material (top); both were 
measured in CDCl3. Expanded in the region δ 9 to 5 ppm. 
 
 The lower spot material isolated from the column was composed mostly of 
compound 30, but it contained the same unknown product, albeit in much smaller 
amount (Figure 33). The aromatic protons are almost unnoticeable, but a small 
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singlet peak is near δ 3.45 ppm. This peak is also present in the higher spot 
material. 
Figure 33. Low spot column separated NMR reaction of thiol and 29. Spectra of 
30 (bottom, in acetone-d6) and column material (top, in CDCl3). 
 An attempt was made to identify the impurity by subtraction of the known 
peaks, i.e. 29 and 30, from the unknown material using features in Topspin, a tool 
for analyzing NMR spectra.
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 The following peak information was obtained: δ 
8.15 ppm (s, 1H), 8.05 ppm (d, 1H), 7.42 ppm (d, 1H), 4.30 ppm (s, 1H), 3.45 
ppm (s, 3H). An epoxide structure was reported from a reaction of 27 or 28 with 
dimethyldioxirane.
90
 This epoxide product has similar non-aromatic peaks. A 
synthesis was attempted with dimethyldioxirane
91
 and the analogous 29 to obtain 
the epoxide for direct comparison to the unknown. Unfortunately, the reaction 
appeared to form a polymer, as white solid precipitated out of a reaction solution 
of acetone and DCM. This solid was either not soluble or very slightly soluble in 
several other organic solvents, including DMSO. 
 The column-recovered materials support the addition-elimination reaction 
between 29 and NAC. This compound may be capable of binding to an enzyme, 
but irreversible inhibition is not likely. The carbanion that is generated upon 
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addition to the olefin would need to form a stable bond with an available 
electrophile (Figure 34). Additionally, the carbanion could undergo lactone ring 
opening instead of elimination of the thiolate nucleophile. That would trap the 
nucleophile in a stronger alkenyl bond. 
 
Figure 34. Two possible products from thiolate reaction with 29. Product A is 
from the carbanion reaction with an electrophile, E
+
. Product B could form if the 
lactone is opens, and the carboxylate is unable to react to reform it. 
 
 The mechanism proposed in Figure 34 is not the only pathway for addition 
of a thiolate. Halo lactone alkenes have been proposed to inactivate serine 
hydrolases with initial attack at the carbonyl carbon. Upon lactone opening, either 
cysteine or another nucleophile would displace the halogen of the reported halo 
lactone alkenes.
92
 A reaction between the thiolate of NAC and the lactone 
carbonyl of 29 (C10, Figure 8) would generate similar resonance structures 
depicted in Figure 34. However, C3 would be a carbonyl carbon with a thiol ester 
at C10. 
 Neither of the compounds examined by NMR was capable of adding a 
thiol (DTT or NAC). Since the enzyme assays were run at or near neutral pH (7.0 
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to 7.4), inactivation by DTT is unlikely. Additional experiments observing the 
rate of the reaction by loss of the carbon-carbon double bond could be inspected 
by UV with these compounds (see Chapter 3.6). If the conjugated carbon-carbon 
double bond appears at a unique location in the UV spectrum, then its 
disappearance, or lack thereof, would determine if incubation with DTT buffer 
can inactivate these compounds. 
 Addition of a strongly basic amine produced the more reactive thiolate, 
which is the expected nucleophile in the catalytic pocket of PTPs. Both of these 
compounds showed evidence for addition of the thiolate. There was no evidence 
of an episulfonium ion from 3. Compound 29 can add thiolate, but generation of 
an episulfonium ion was never expected. An addition-elimination reaction with 29 
was confirmed by isomer isolation. An unknown product was also being 
generated, but confirmation of epoxide formation was not successful. 
3.5 Cancer Cell and Protein Tyrosine Phosphatase Assays of Bromo Nitro 
Lactones 
 In contrast to the original cinnamic acid design, the nitro lactone 
analogues displayed much greater activity despite the lower dosage (10 μg/mL) 
used in SRB assays (Table 5). Compounds 11, 12 and 26 are very similar to 33, 
34, 35 and 37. Furthermore, all of these lactones were tested in the SRB assay, so 
they can be compared directly. Presumably, the difference in activity for the 
lactones relies on the change to the nitro group from the carboxylic ester and not 
on the halogen. Unlike the hydrogen-iodide elimination products isolated when 26 
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was treated with base, the bromo nitro lactones will preferentially be deprotonated 
alpha (C2) to the nitro group, for 35 and 37 to undergo opening of the lactone 
ring. 
 This lactone ring opening to generate a reactive Michael-acceptor in 
alkaline solution has been described for the non-halogenated precursor 31.
66
 This 
would generate the Michael-acceptor, which may be the actual inhibitor that 
forms from 35 and 37. There are published reports that investigated the ability of 
several nitrostyrenes to inhibit cell growth in a couple of cancer-cell lines.
51
 These 
cancer cell lines were generated by the Rous sarcoma virus infection of hamster 
fibroblasts.
93
 Two cell lines were made with different levels of activity. The same 
cancer cell lines in a follow up study,
51
 and 31 was found to be somewhat active 
around 50 µM. The authors proposed that nitrostyrene was generated and acted as 
the reactive compound (not experimentally supported). 
 Surprisingly, 33, and to a lesser extent 34, was active against some cell 
lines, too. Since no hydrogen is attached to the carbon with the nitro group, these 
compounds were not expected to undergo lactone opening that would create a 
reactive Michael-acceptor. However, there was a possibility of hydrogen-bromide 
elimination from C3 and C2. This is similar to the hydrogen-iodide elimination 
from 25 and 26 to form 27–30. A lactone alkene would be generated, but bromine 
would be substituted on the olefin in place of the hydrogen (see BNLA in Figure 
12). Evidence of this possible formation is discussed in Chapter 3.6. 
 After the promising SRB assay results, PTP assays were retried. However, 
more PTP targets were needed to determine the breadth of potential inhibition. 
81 
Millipore, Ltd., offered enzyme assays against ~ 21 PTPs. Five potential 
inhibitors were assayed against five of these PTPs using the substrate 6,8-
difluoro-4-methylumbiliferyl phosphate, DIFMUP, which produces a fluorescent 
molecule, 6,8-difluoro-7-hydroxy-4-methylcoumarin, DIFMU (Figure 35).
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Table 5. Human Cancer Cell Line Growth Inhibition (SRB Assay) for 33, 34, 35 
and 37; values in µM 
 
Compound 
 
BXPC-3 MCF-7 SF-268
a
 NCI-H460 KM20L2 DU-145 
33 
(28.5) 
GI50 
TGI 
LC50 
5.3 
11.1 
23.3 
15.4 
ND 
ND 
20.8 
ND 
ND 
ND 
ND 
ND 
12.1 
ND 
ND 
ND 
ND 
ND 
34 
(21.0) 
GI50 
TGI 
LC50 
9.6 
ND 
ND 
ND 
ND 
ND 
2.8 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
35 
(36.8) 
GI50 
TGI 
LC50 
8.1 
15.8 
32.9 
8.9 
18.7 
ND 
13.9 
ND 
ND 
12.9 
ND 
ND 
8.1 
15.3 
32.7 
11.9 
34.1 
ND 
37 
(25.3) 
GI50 
TGI 
LC50 
5.5 
12.0 
ND 
22.2 
ND 
ND 
2.2 
ND 
ND 
13.6 
ND 
ND 
16.9 
ND 
ND 
ND 
ND 
ND 
BXPC-3 (pancreas adenocarcinoma), MCF-7 (breast adenocarcinoma), SF-268 
(CNS glioblastoma), NCI-H460 (lung large cell), KM20L2 (colon 
adenocarcinoma), DU-145 (prostate carcinoma). 
a
 The SF-268 cell line was unstable. Thus the results displayed may not be 
accurate. 
The assay employed a maximum dose of 10 µg/mL, and the concentration 
corresponding to that dose is displayed in parentheses below each compound  
ND: No Detection of inhibition at the highest concentration tested as shown in 
micromolarity below the compound number. 
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Figure 35. Dephosphorylation of DIFMUP to DIFMU by a tyrosine phosphatase. 
The DIFMU product is excited at 358 nm and emission read at 455 nm.
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 The five compounds that were tested included 24 and 29 along with 33, 35 
and 37. A DMSO stock solution of each compound was prepared. The solubility 
of all but 29 was confirmed to be at least 100 µM in phosphate-buffered saline, 
pH 7.4 (see Experimental). Therefore, they were tested at 100 µM, except 29 was 
tested at the lower concentration of 50 µM, at which it was soluble (Table 6). 
There was no pre-incubation step during this assay, which was run at a pH 7.2 
with a DTT concentration of 0.1 mM. A buffer suitable for each PTP was also 
selected for the assay (correspondence with Millipore).  
 The DIFMUP assay supports the results of the pNPP assay in that 24 and 
29 are not active against PTP1B. The only enzyme inhibited by 24 and 29 was 
SHP-2, but the inhibition was minimal given the high inhibitor concentration. 
Repeating this assay with pre-incubation of these compounds with enzyme may 
lead to improved inhibition. As of now, there is no evidence to imply that their 
ability to inhibit cell-growth was a result of targeting PTPs. 
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Table 6. PTP activity (% of control) with 24, 29, 33, 35 and 37 
 
PTP 
 Human origin 
24  
(100 μM) 
29  
(50 μM) 
33  
(100 μM) 
35  
(100 μM) 
37  
(100 μM) 
CD45 85 102 0 3 4 
PTP1B 118 102 39 15 16 
TCPTP 112 115 0 6 9 
SHP-1 102 103 0 7 8 
SHP-2 63 77 0 1 1 
Displayed in each column is the % activity of a particular PTP enzyme, all human 
origin, with a test compound present. In parentheses is the assay concentration of 
test compound. The % activity is calculated from the enzyme’s ability to 
dephosphorylate DIFMUP without test compound present. 
 
The superior performance of the bromo nitro lactones in the SRB assay 
was also observed in the DIFMUP enzyme assay. Even lacking a pre-incubation 
step, they proceeded to dramatically reduce the activity of all the PTPs. 
Interestingly, the ubiquitous PTP1B enzyme seemed to be the most resistant to 
inhibition in each case. Unfortunately, PTP selectivity cannot be evaluated from 
this initial examination of a single concentration of applied test compound. 
Surprisingly, 33 inhibited four of the five enzymes essentially completely. Its 
activity was thought to arise from elimination of HBr that produced a bromo nitro 
lactone alkene (BNLA). This possibility was further investigated and supported. 
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3.6 Characterization of Bromo Nitro Lactones by Ultraviolet Spectroscopy 
The UV spectra of 33, 35 and 37 were collected in phosphate-buffered 
saline. Only 33 showed variation over the course of one hour while in a 
phosphate-buffered saline solution (Figure 36). The UV spectra for both 35 and 
37 remained essentially constant for over one hour (not shown). 
 
Figure 36. UV spectra of 33 in phosphate-buffered saline for 1 hour. Compound 
33 was dissolved in DMSO, then diluted into PBS, pH 7.4, to 100 µM and 
monitored in a Costar UV multi-well plate with a final volume of 100 µL (2% 
DMSO) for 1 hour at room temperature. 
 
Given its structure, 33 is not expected to absorb in the region from 300–
400 nm. However, elimination of hydrogen bromide would generate a carbon-
carbon double bond that has extended conjugation from the aromatic ring to the 
nitro group. In general, nitrostyrenes have a distinct absorption maximum 
between 300 and 350 nm,
96
 and the UV spectrum of the C2-bromo substituted 
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nitrostyrene has been reported to have a λmax at 324 nm.
97
 When 33 was allowed 
to stand in phosphate-buffered saline, pH 7.4, a λmax at 345 nm with ε = 3.8 × 10
3
 
M
-1
cm
-1
 developed. The elimination is likely favored due to the conjugation 
between the nitro group and the aromatic ring to form BNLA (Figure 37). 
 
Figure 37. Dehydrobromination of 33 to produce bromo nitro lactone alkene, 
BNLA. The E-alkene is shown, but the Z-configuration is also possible. A 
stepwise elimination is shown, but the reaction may be concerted (E2). 
 
 The product BNLA may further hydrolyze to produce an enol that can 
tautomerize to a ketone in a subsequent step (Figure 38). It is currently unknown 
if this occurred in the PBS solvent. If hydroxide does add, then the enol may be 
preferred in alkaline solution, as extended conjugation from the aromatic ring to 
the nitro group would remain intact. 
 
Figure 38. The tautomers of BNLA after addition of hydroxide. 
 
 The above enol may not be the source of the large peak that is generated 
around 345 nm in Figure 36. A nitrostyrene with two bromines substituted on the 
carbon-carbon double bond in place of hydrogens has been reported as not having 
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any absorption in this region.
98
 An X-ray structure confirmed that the olefin and 
aromatic ring were not in the same plane. The authors believed this was due to the 
steric strain caused by the presence of the olefinic bromine nearer to the phenyl 
ring. Thus, the enol double bond may not be coplanar with the aromatic ring if the 
steric strain between the hydroxyl and carboxylate is greater than the electrostatic 
interaction between the carboxylate and the partially charged proton of the 
hydroxyl group. In other words, BNLA may form in the buffer as a stable but still 
reactive product.  
Compound 31 reportedly generated a small hump at 319 nm from the 
conjugated alkene that forms upon opening of the lactone when it is dissolved in 
aqueous alkaline solution.
66
 This peak decreased significantly in a few minutes as 
a new peak at 248 nm appeared. This was attributed to the nitronate that formed 
after hydroxide added to the carbon-carbon double bond. A large hump for 35 and 
37 was not present in water, but it was immediately generated when the solutions 
were made more alkaline (Figure 39). 
 Unlike the reported UV spectra of 31, the peak appearing around 340 nm 
for 35 and 37 does not decrease after 5 minutes in solution (not shown). A 
hyperchromic effect is noted for 35 with addition of NaOH. For 37, this effect is 
not as great, but the sharp spike at 235 nm and the small shoulder at 270 nm have 
combined. Regardless of these slight differences, the appearance of the hump 
around 340 nm is still believed to arise from opening of the lactone (Figure 40). 
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Figure 39. UV spectra of 35 and 37 in water and with sodium hydroxide. 
Collected in a Costar UV multi-well plate with a final volume of 100 µL (2% 
DMSO). Proposed nitro olefin peaks appearing at 345 nm (ε = 4.3 × 103 M-1cm-1) 
for 35 and 340 nm (ε = 2.3 × 103 M-1cm-1) for 37. 
 
 
Figure 40. Loss of a proton and generation of a conjugated bromo nitro alkene 
from 35. The same mechanism can be extended to 37. 
 
 Both 35 and 37 appear to be stable in buffered solution, but the opened 
lactones are halogenated Michael acceptors that are the suspected inhibitory 
compounds. Additional UV spectra were collected for 35 a few months after the 
spectra in Figure 39 were collected. The original DMSO-stock solution was 
diluted into PBS buffer and stored for 19 hours at room temperature prior to 
acquisition of the UV spectrum (Figure 41). When the 19-h solution is compared 
to immediate addition of 35, a small hump has noticeably developed at 340 nm (ε 
= 2.1 × 10
3
 M
-1
cm
-1
) for the 19 h solution. There is a possibility 35 is slowly 
generating the reactive olefin as shown in Figure 40. 
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Figure 41. UV spectra of 35 in phosphate-buffered saline, 0 and 19 h. Two 
spectra were acquired for each time, and the average of the two spectra are 
plotted. The hump is centered at 340 nm (ε = 2.2 × 10-3 M-1cm-1). 
 
3.7 Experiments with Bromo Nitro Lactones and Thiols 
 An NMR experiment with 33 and triethylamine in CDCl3 was carried out 
to investigate the potential dehydrobromination reaction (Figure 36). As noted, 
during the Henry reaction between bromonitromethane and 2-formylbenzoic acid 
(Chapter 2.9), a by-product formed along with compound 36 (the diastereomer of 
35). This by-product had an aromatic doublet shifted downfield to about δ 8.4 
ppm, and no other distinguishable peaks were seen outside of the aromatic region 
(see Figure 11). The lack of peaks appearing outside of the aromatic region and 
the downfield shifted doublet were rationalized as arising because of the 
formation of BNLA (Figure 36). The NMR experiment with 33 and triethylamine 
showed two doublets downfield between δ 8.6 and 8.3 ppm (Figure 42).  
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Figure 42. NMR experiment with 33 and triethylamine. 
1
H NMR of 33 (top) and 
33 + NEt3 (bottom) in CDCl3. Circled, doublets from suspected formation of E 
and Z isomers of BNLA. Boxed, symmetric peaks from suspected phthalate 
analogue. 
 The singlet peak for the lone, non-aromatic proton of 33 (on C3) that is 
located at about δ 6.4 ppm was gone in less than 15 minutes. Surprisingly, two 
nearly symmetric aromatic multiplets appeared as the preeminent peaks. The 
doublets between δ 8.5 to 8.4 ppm are likely due to anisotropy from the bromine 
or nitro group upon formation of E or Z alkene (BNLA).
79
 Two low-integrating 
singlets are present, too (δ 8.55 and 6.85 ppm), and they could be from 
intermediates. The symmetric multiplets between δ 7.5 and 7.7 ppm formed in 
preference to anything else. 
The newly generated lactone alkene (BNLA) is a Michael acceptor that is 
the expected reactive molecule in assays. It did not appear to be too reactive in 
UV experiments using PBS, as the proposed nitro-alkene hump did not vanish 
over time. However, there is a possibility that it may be too reactive in this NMR 
experiment with NEt3. A subsequent transformation is occurring in the NMR 
experiment, and this product may be responsible for the enzyme and cell-growth 
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inhbition. The CDCl3 solvent used does have a small amount of water present. 
Thus, hydroxide formation from water and triethylamine would occur, and 
addition of the hydroxide to the alkene could result in further transformations that 
produce a phthalate or similar analogue (Figure 43). 
 
Figure 43. The proposed transformation from 33 to phthalate. Upon loss of HBr 
(step 1), hydroxide can add at two places; only addition to the conjugated nitro 
alkene is shown (step 2). Loss of bromonitromethane produces phthalate (step 3). 
 Thus, the singlets that appeared in the NMR spectrum during the reaction, 
at δ 8.55 and 6.85 ppm, may be from an intermediate. Only addition of hydroxide 
to the conjugated nitro alkene is shown in Figure 43, but it may add to the 
carbonyl carbon too. Analogous compounds have been proposed to react with 
hydroxide or methoxide via the carbonyl carbon prior to undergoing 
rearrangements (i.e., dibromobenzalphthalide).
99 
Similar rearrangements would 
91 
generate additional intermediates and products that are not shown. Regardless, 
NMR experiments indicated fast transformations with BNLA that seemed to be 
produce phthalate analogues.
 
 Isolation of BNLA was attempted, but phthalic acid formation seems to 
occur even when dry reaction conditions were used. A reaction with t-butoxide in 
t-butyl alcohol under nitrogen was attempted, but it was very slow. The crude 
product NMR spectrum had signals for unreacted 33 with a small symmetric 
peak. The 
13
C NMR spectrum of this crude material was acquired, and thirteen 
peaks appeared. Nine of the peaks belong to unreacted 33, and the other four 
peaks were from the formation of the symmetric product believed to be a 
phthalate analogue (in DMSO-d6, 400 MHz, δ 169.1, 168.2, 144.1, 135.8, 133.2, 
132.0, 131.2, 128.7, 126.5, 126.3, 124.5, 87.5, 83.2). 
 If a rearrangement of 33 can occur similarly to what was described by 
Alexander, et al.
79
 or Shchukina,
99
 then a compound like 2-nitro-1,3-indandione 
or a similar structure may form. Five carbon peaks would be expected to appear in 
13
C NMR, but only four were found for 2-nitro-1,3-indandione.
100
 However, the 
furthest downfield peak for that compound is located at δ 181.6 ppm in the same 
solvent as the reaction product with 33. Therefore, elimination of 
bromonitromethane, which can polarize the carbon-carbon bond and stabilize the 
resulting charge, seems to be the most plausible pathway. Similarly, 
phenylnitromethane has been proposed as a good leaving group for o-
[nitro(phenyl)acetyl]benzoic acid (a hydrogen substituted at C2 by phenyl and C3 
92 
by hydroxyl, Figure 8) coming apart in alkaline solution with formation of 
phthalic anhydride.
101
 
 Triethylamine and DCM were separately dried and distilled before storage 
over Molecular Sieves, and subsequent reactions with 33 were run under a 
nitrogen atmosphere. A crude product from a reaction of 33 with NEt3 in DCM 
was isolated when the reaction was run very cold (Figure 44). From the 
1
H NMR 
spectrum, the crude product consisted of unreacted 33 and the two lactone alkene 
products. There is evidence of small, symmetric peaks, too (δ 8.2 ppm and the 
corresponding symmetric peak is likely masked by other aromatic protons), which 
would mean a phthalate analogue formed again. However, this lone peak is small 
and shifted downfield from what was seen previously (Figure 42). The reduced 
intensity of this peak from this reaction run at lower temperature supports initial 
formation of BNLA prior to any phthalate. The downfield shift is possibly from 
the lack of an amine base being present like in the NMR experiment.  
Figure 44. Crude material from a low reaction between 33 and triethylamine. 
1
H 
NMR of 33 (top) and crude material from reaction of 33 with NEt3 between -20 
and 0 °C (bottom); both in CDCl3. 
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 Attempts were also made to isolate a product from reaction of 35 with a 
base-generated thiolate, similar to Fekry, et al.
54
 An initial 
1
H NMR reaction 
mixture of β-mercaptoethanol and NEt3 showed some promise (Figure 45). 
Figure 45. Reaction of 35 with β-mercaptoethanol and triethylamine. Bottom: 35; 
middle: 35 + β-mercaptoethanol; top: 35 + β-mercaptoethanol + NEt3; in CDCl3. 
 
 As the bottom two spectra in Figure 45 are almost identical, compound 35 
does not react with just β-mercaptoethanol. Addition of NEt3 resulted in several 
new doublets, and two multiplets, at δ 8.35 and 6.20 ppm. The latter multiplet is 
commonly seen with 31, and there are two more multiplets upfield (not shown) 
between δ 5.0 and 4.7 ppm. These peaks are also from 31. The new doublets were 
initially thought to be from thiolate addition. Unfortunately, the same peaks 
developed when 35 was treated with only NEt3 (Figure 46). 
 The NMR reaction mixture was treated with acetic acid, in an amount 
equivalent to NEt3, to check for any changes and to neutralize the amine base 
(Figure 46, top). It also helped resolve certain peaks. The NMR spectrum of 33 
was included because a singlet was formed in the location normally seen for its 
non-aromatic proton (C3). While a dehydrobromination reaction occurred when 
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NEt3 and 33 were combined, the same elimination was not expected for 35 (i.e., 
HBr elimination between C2 and C3 in Figure 8). A downfield doublet would be 
expected to form very far downfield (from the proton on C9) if that were the case, 
but a multiplet formed instead. 
Figure 46. Reaction of 35 with triethylamine. Bottom to top: compound 35, 
compound 33, 35 + NEt3 at 10 min, then 48 hours and finally with an added 
equivalent of AcOH. All spectra were measured in CDCl3. 
 
 A dehydrobromination from 35 would result in a lactone-alkene structure 
similar to 29, and the singlet near δ 6.4 ppm may be attributed to that olefinic 
proton. However, NEt3 appears to have removed either the proton, or possibly the 
bromine, next to the nitro group (Figure 47). Two sets of doublets appeared 
between δ 6.7 to 6.0 ppm after acetic acid was added to the NMR mixture (Figure 
46, top). At about δ 6.1 ppm, one set of doublets appear (J = 7.5 Hz), which are in 
the same location as the doublets for 36 (the diastereomer of 35). The doublets for 
35, which were separated by 0.2 ppm prior to the reaction, also resolved (J = 3.2 
Hz), but one of the proton peaks (C2) has shifted about 0.3 ppm downfield. Also, 
this set of doublets is now about 0.4 ppm apart. The appearance of doublets for 36 
95 
was expected, as the proton on C2 is exchangeable, and a base should scramble 
any initial stereochemistry at that carbon. 
 Triethylamine was not expected to be act as a reducing agent capable of 
removing a bromine, but reactions between amines and organobromides or 
amines and bromine are known.
102, 103
 Peaks for 31 are still observed when only 
the amine base was used (Figure 46). The singlet at δ 6.4 ppm is attributed to the 
generation of 33. This singlet is not present when a thiol is in the reaction 
mixture, though (Figure 45). In this case, formation of 31 is either preferred or 33 
forms and reacts quickly. 
 
Figure 47. Reduction or oxidation of 35 by triethylamine. NEt3 either 
deprotonates or debrominates 35 (reaction 1). Both carbanions are formed 
reversibly, which would result in 35 or 36 being formed. Additionally, the 
carbanions can react to form 33 (reaction 2) or 31 (reaction 3). 
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 Additional experiments were done with 35 in various systems, and the 
crude material analyzed by NMR spectroscopy (Table 7). Several experiments 
were done with PBS, pH 7.4, being used. A new thiol was also used, the sodium 
salt of β-mercaptoethanesulfonate (MESNA). In every reaction with an amine 
base or thiol present, 31 was recovered in majority. When 35 was stirred in PBS 
buffer without base or thiol added, only 35 and 36 were recovered. Only 
reversible deprotonation of 35 would afford both isomers. In other words, the 
buffered solution could deprotonate 35 and possibly generate a reactive alkene 
(Figure 40), but there is no loss of bromide in solutions of only buffer. 
Regardless, no thiol-addition products could be isolated from any reaction 
mixtures to confirm the existence of this reactive alkene. Even when a slightly 
acidic buffer was used, pH 6.81, the reduction to 31 occurred as long as MESNA 
was in the reaction mixture. This indicates deprotonation, or even lactone 
opening, is unnecessary for removal of the bromine, i.e. it is removed directly 
from 35. 
 A biphasic reaction mixture was also employed (Table 7). Compound 35 
is soluble in DCM and deprotonation, with potential lactone opening in a 
subsequent step, would result in an intermediate that is soluble in the aqueous 
phase. MESNA is ionic and not likely to transfer into DCM; it would only be in 
the aqueous phase. The attempted generation of the reactive alkene prior to 
coming into contact with a thiol did not produce a new product, though. 
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Table 7. Reaction of 35 with Thiols in Various Systems. 
 
Thiol (eq) Base (eq) Solvent(s) 35:36:31 
MESNA (1.2) Pyridine (3.7) Pyridine Only 31 
MESNA (1.1) - PBS 1.00:0.07:0.58 
- - PBS 1.00:0.53:0 
MESNA (1) - PBS
a
 1.00:0.22:0.79 
MESNA (1.1) - DCM and PBS 1.00:0.52:1.40 
DTT (1) - PBS 1.00:0.07:2.60 
All reactions started with 35. PBS, pH 7.4, served as the base and solvent in most 
experiments. Only one reaction did not include a thiol. The molar equivalents of 
thiol or base in comparison to 35 are in parentheses. 
a
 PBS, pH 6.81. 
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4 EXPERIMENTAL 
 
All melting points were taken in an Electrothermal® melting point apparatus and 
are uncorrected. 1H and 13C NMR were acquired with the solvent and radio 
frequency (in MHz) listed. When TMS was included in the solvent, the peak 
locations are listed downfield from TMS. If TMS is not listed, spectra were 
referenced to the solvent residual peak ± 0.01 ppm.104 Solvents used in reaction 
mixtures were distilled and dried over Molecular Sieves prior to use unless 
specified. All reactants were used as purchased without purification unless noted. 
Safety information (MSDS) is provided by the chemical supplier and is available 
free of charge on their website (ex. http://www.sigmaaldrich.com/safety-
center.html). Elemental analysis were performed by Atlantic Microlabs, Inc. 
(Norcross, Georgia). Measurements for the UV spectra of compounds and the 
pNPP assay were done on a BioTek Synergy 2 Multi-mode Microplate Reader 
using a SQ Xenon Flash light source. 
Methyl (E)-(2-methoxycarbonylphenyl)prop-2-enoate (1): 
Acetyl chloride (1 mL) was slowly added to 25 mL of methanol in a 100-mL 
round-bottom flask while on ice. The reaction mixture was refluxed for 10 min 
prior to addition of 2-carboxycinnamic acid (381 mg, 2 mmol). After refluxing 2 
h, the reaction mixture was concentrated by vacuum rotoevaporation and passed 
through a short silica gel column with DCM as the eluting solvent. A viscous clear 
oil of 1 was recovered upon evaporation of DCM (420 mg, ~ 95%). 1H NMR (300 
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MHz in CDCl3) δ 8.48 (d, 1H, J = 15.9 Hz), 7.98 (d, 1H, J = 7.8 Hz), 7.57 (m, 
2H), 7.44 (t, 1H), 6.34 (d, 1H, J = 15.9 Hz), 3.94 (s, 3H), 3.82 (s, 3H). 
Methyl 2,3-dichloro-3-(2-methoxycarbonylphenyl)propanoate (2): 
KMnO4 (0.73 g, 4.62 mmol) and benzyltriethylammonium chloride (bteac, 1.04 g, 
4.57 mmol) were stirred in 20 mL of dry DCM. The resulting dark purple solution 
was cooled on ice for 20 min. Four equivalents of distilled TMSCl (2.00 g, 18.4 
mmol) was slowly added to the stirred solution, which gradually took on a dark 
green color. The reaction mixture was allowed to warm to room temperature 
before 1 (1.00 g, 4.55 mmol) was added. The reaction was terminated, as multiple 
spots appeared on TLC, by addition of 0.1 M sodium thiosulfate to the organic 
phase. After extraction of the organic phase, it was washed with brine prior to 
being dried over anhydrous sodium sulfate. A silica gel column was used to 
separate the mixture (elution with 1:1 hexanes–chloroform). Recrystallization 
from DCM–hexanes yielded 2 (640 mg, 48%) as a white solid, mp 70.5–72 °C. 
1H NMR (400 MHz in CDCl3) δ 7.97 (d, 1H, J = 8.0 Hz), 7.69 (d, 1H, J = 7.6 
Hz), 7.60 (t, 1H, J = 7.6, 7.6 Hz), 7.44 (t, 1H, J = 7.6, 8.0 Hz), 6.62 (d, 1H, J = 
10.4 Hz), 4.75 (d, 1H, J = 10.4 Hz), 3.95 (s, 3H), 3.88 (s, 3H); 13C NMR (100 
MHz in CDCl3) δ 167.5, 167.0, 137.7, 132.6, 130.6, 130.0, 128.9, 128.6, 59.2, 
55.8, 53.4, 52.6. Anal. Calcd (%) for C12H12Cl2O4: C, 49.51; H, 4.15. Found: C, 
49.30; H, 4.11. 
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Methyl (Z)-2-chloro-3-(2-methoxycarbonylphenyl)prop-2-enoate (3): 
In 2 mL of DCM was dissolved 2 (300 mg, 1.03 mmol). Triethylamine was then 
added (110 mg, 1.10 mmol), and the reaction was monitored by TLC. The mixture 
was washed successively with ~ 5 mL of 1.0 M HCl and brine and dried with 
sodium sulfate. The crude product was crystallized multiple times from 
DCM-hexanes to yield 3 (90 mg, 36%) as a white solid, mp 85.5–87.5 °C. 1H 
NMR (500 MHz in CDCl3) δ 8.45 (s, 1H), 8.05 (d, 1H, J = 12.5 Hz), 7.66 (d, 1H, 
J = 8.0 Hz), 7.57 (t, 1H, J = 8.0, 12.5 Hz), 7.44 (t, 1H, J = 7.5, 8.0 Hz), 3.90 (s, 
3H), 3.88 (s, 3H). 
Methyl 2,3-dibromo-3-(2-methoxycarbonylphenyl)propanoate (4): 
Bromine (0.1 mL) and 1 (250 mg, 1.14 mmol) were stirred in DCM until the 
reaction was judged to be complete by TLC. The excess bromine was evaporated, 
and the crude material was applied to a silica gel column with DCM. Collection 
of the product spots and evaporation of DCM provided 4 as a colorless solid in 
quantitative yield, mp 94–97 °C. 1H NMR (300 MHz in CDCl3) δ 7.95 (d, 1H, J = 
7.8 Hz), 7.62 (m, 2H), 7.60 (t, 1H, J = 7.6 Hz), 6.80 (br s, 1H), 4.90 (br s, 1H), 
3.98 (s, 3H), 3.91 (s, 3H). Anal. Calcd (%) for C12H12Br2O4 : C, 37.93; H, 3.18. 
Found: C, 37.91; H, 3.13. 
Methyl (Z)-2-bromo-3-(2-methoxycarbonylphenyl)prop-2-enoate (5) and 
Methyl (E)-2-bromo-3-(2-methoxycarbonylphenyl)prop-2-enoate (6): 
Triethylamine (30 mg, 0.30 mmol) and 4 (100 mg, 0.26 mmol) were combined 
and stirred overnight. Two TLC spots developed below the spot for 4 with the 
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lower of the two spots being 5. The products were separated by silica gel 
chromatography using DCM and hexanes and recrystallized from DCM and 
hexanes to yield pure 5 (10 mg, 13%) as a colorless solid, mp 79–80 °C. Isolation 
of 6 yielded an oil that was slightly contaminated with 5. 
(5) 1H NMR (500 MHz in CDCl3) δ 8.66 (s, 1H), 8.07 (d, 1H, J = 7.3 Hz), 7.60 
(d, 2H, J = 7.7 Hz), 7.47 (m, 1H), 3.92 (s, 3H), 3.90 (s, 3H). Anal. Calcd (%) for 
C12H11BrO4: C, 48.18; H, 3.71. Found: C, 48.30; H, 3.62. 
(6) 1H NMR (500 MHz in CDCl3) δ 8.04 (d, 1H, J = 7.8 Hz), 8.00 (s, 1H), 7.50 (t, 
1H, J = 7.5 Hz), 7.42 (t, 1H, J = 7.5 Hz), 7.23 (d, 1H, J = 7.6 Hz), 3.91 (s, 3H), 
3.51 (s, 3H). 
(3-Oxo-1,3-dihydro-2-benzofuran-1-yl)acetic acid (7): 
2-Carboxycinnamic acid (0.95 g, 4.99 mmol) was refluxed in 10 mL acetic acid 
and 0.92 g polyphosphoric acid for 2 h before pouring into an Erlenmeyer flask 
with 50 mL ice water. After stirring for 1 h, the white precipitate was vacuum 
filtered and washed with water. After drying, 7 was recovered (958 mg, 100%) as 
a white solid, mp 151–153.5 °C. 1H NMR (500 MHz in acetone-d6 and TMS) δ 
7.85 (d, 1H, J = 7.7 Hz), 7.77 (m, 2H), 7.62 (t, 1H, J = 7.3 Hz), 5.92 (dd, 1H, J =  
5.1, 7.5 Hz), 3.15 (dd, 1H, 4.75, 16.8 Hz), 2.87 (dd, 1H, 7.8, 16.8 Hz). 
Methyl (3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (8): 
In a RBF were dissolved 7 (1.146 g, 5.96 mmol) and cesium carbonate (flame 
dried prior to using, 1.90 g, 5.83 mmol) in 8 mL of MeCN. After being stirred at 
room temperature for about 5 min, a salt precipitated. Iodomethane (3.70 g, 26.1 
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mmol) was dissolved in 17 mL of MeCN and added to the salt. The reaction 
mixture was refluxed on a sand bath for about 1 h, whereupon the reaction was 
complete as judged by TLC. MeCN was almost completely evaporated, and 
EtOAc was added to the solid. The mixture was filtered, and the filtrate was 
evaporated to yield a pale yellow oil (1 g). The oil crystallized upon dissolving in 
hot EtOAC and hexanes followed by cooling. This initial precipitate was 
repeatedly recrystallized from EtOAc and hexanes to yield 8 as small white 
needles in two crops (820 mg and 140 mg, total 960 mg, 78%). 
Ethyl (3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (9): 
7 (198 mg, 1.03 mmol) was dissolved in 12 mL MeCN with cesium carbonate 
(338 mg, 1.04 mmol) and stirred at room temperature for 5 min as the milky white 
solution turned into a salt-like mixture. Iodoethane (730 mg, 4.67 mmol) was 
added, and the mixture was stirred for 1 h at room temperature. The reaction 
mixture was then heated at about 60 °C for 1 h and stirring was continued at rt for 
2 h. The reaction mixture was filtered, and the filtrate evaporated and collected in 
a large volume of chloroform (60 mL). The organic solvent was washed with 2% 
aq NaHCO3 (3 × 10 mL), then brine before being dried with sodium sulfate and 
rotary evaporation of the solvent to yield 9 (189 mg, 83%) as a white solid. 1H 
NMR (500 MHz, CDCl3) δ 7.89 (d, 1H, J = 7.7 Hz), 7.68 (t, 1H, J = 7.5 Hz), 
7.54 (t, 1H, J = 7.5 Hz), 7.50 (d, 1H, J = 7.7 Hz), 5.87 (t, 1H, J = 6.6 Hz), 4.19 (t, 
2H, J = 7.2 Hz), 2.89 (dd, 2H, J = 3.6, 6.5 Hz), 1.25 (t, 3H, J = 7.2 Hz). This 
product was not used in a future synthesis. 
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2-[(1E)-3-methoxy-3-oxoprop-1-en-1-yl]benzoic acid (10): 
In a RBF was dissolved 8 (820 mg, 3.98 mmol) in 2 mL DCM. Triethylamine 
(448 mg, 4.44 mmol) was added, and the reaction mixture was stirred at room 
temperature while being monitored by TLC. More triethylamine (155 mg, 1.53 
mmol) was added as TLC showed starting material present after being stirred 
overnight. Upon completion of the reaction judged by TLC, 5 mL of 1 M HCl 
(aq) was slowly added while a precipitate formed. After being stirred for more 
than 30 min, water (20 mL) was added prior to filtration of the solid, which was 
washed with more water (460 mg 10, 56%). Extraction of the aqueous filtrate 
with EtOAc (3 × 12 mL) yielded additional 10 as an impure, light yellow oil (317 
mg, 39%). 1H NMR (400 MHz in acetone-d6) δ 8.55 (d, 1H, J = 16.0 Hz), 8.02 (d, 
1H, J = 8.0 Hz), 7.80 (d, 1H, J = 8.0 Hz), 7.62 (t, 1H, J = 7.6 Hz), 7.52 (t, 1H, J 
= 7.6 Hz), 6.41 (d, 1H, J = 16.0 Hz), 3.74 (s, 3H). 
(R*, R*)-Methyl chloro(3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (11) and 
(R*, S*)-Methyl chloro(3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (12): 
Benzyltriethylammonium chloride (511 mg, 2.24 mmol) and potassium 
permanganate (343 mg, 2.17 mmol) were stirred in 8 mL of DCM. 
Chlorotrimethylsilane (990 mg, 9.17 mmol) was added, and the solution turned 
dark green. 10 (420 mg, 2.03 mmol) was not entirely soluble in DCM (10 mL), 
but an attempt was made to carry out the reaction with TLC monitoring. After 
being stirred 7 h on ice, the reaction mixture was poured into 30 mL of 0.1 M 
sodium thiosulfate (aq), and the organic layer was extracted. The aqueous layer 
was also extracted with EtOAc (3 × 15 mL). A viscous brown oil was recovered 
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(394 mg) and 1H NMR of this crude material showed mostly ring closure with 
chlorine addition and a very small amount of chlorine-olefin addition. In TLC 
with EtOAc:hexanes (1:4) with 1% EtOH, a spot moving with the solvent front 
was seen, along with two other spots (Rf 0.33 and 0.20). Silica gel 
chromatography with 10 to 20% EtOAc in hexanes to isolate the two spots 
resulted in recovery of 11 (85 mg, 17%, > 95% by 1H NMR) as a light yellow oil 
and 12 (49 mg, 10%) as a colorless solid. 
11 1H NMR (400 MHz, acetone-d6): δ 7.87 (1H, d, J = 8 Hz), 7.79 (1H, t, J = 8 
Hz), 7.69 (2H, m), 6.12 (1H, d, J = 4.8 Hz), 5.19 (1H, d, J = 4.8 Hz), 3.85 (3H, s). 
IR peaks 𝜈 (cm-1): small, sharp peaks: 3033, 2955, 1612 and 1597; medium 
intense peaks: 1466, 1436, 1354, 1110, 895, 865, 838, 798; intense peak 1763, 
1281, 1198, 1169, 1060, 997, 687. 
12 1H NMR (400 MHz, CDCl3 and TMS): δ 7.93 (1H, d, J = 7.6 Hz), 7.74 (1H, t, 
J = 7.6 Hz), 7.57 (2H, m), 6.05 (1H, d, J = 3.6 Hz), 4.83 (1H, d, J = 3.6 Hz), 3.85 
(3H, s). 
Methyl (2E)-3-(2-nitrophenyl)prop-2-enoate (13): 
In a 250-mL RBF in ice was added 2-nitrocinnamic acid (950 mg, 4.92 mmol) 
with 100 mL of MeOH. Acetyl chloride (5 mL) was added slowly, and the 
solution was refluxed for 90 min. MeOH was evaporated, and the crude was 
dissolved in DCM, which was washed with water and brine to yield 13 (1.0 g, 
98%) as a slightly tan-colored solid. This was used without further purification to 
make 14. 1H NMR (400 MHz in CDCl3) δ 8.12 (d, 1H, J = 16.0 Hz), 8.04 (d, 1H, 
105 
J = 8.0 Hz), 7.64 (m, 2H), 7.55 (t, 1H, J = 6.8, 8.0 Hz), 6.37 (d, 1H, J = 16.0 Hz), 
3.83 (s, 3H). 
Methyl 2,3-dichloro-3-(2-nitrophenyl)propanoate (14): 
KMnO4 (0.62 g, 3.93 mmol) and benzyltriethylammonium chloride (0.88 g, 3.89 
mmol) were stirred in DCM (10 mL). The resulting dark purple solution was 
cooled, and cold TMSCl (~ 1.68 g, 15.57 mmol) was added. To the now green 
solution was added 13 (0.81 g, 3.90 mmol). After several hours, the color faded, 
and TLC showed the reaction to be incomplete. KMnO4 (0.62 g, 3.93 mmol), 
benzyltriethylammonium chloride (0.89 g, 3.90 mmol) and TMSCl (~ 1.67 g, 15.5 
mmol) were prepared as above and added to the reaction mixture. After several 
more hours, the color faded and TLC showed incomplete reaction. Additional 
chlorinating reagent was prepared with KMnO4 (0.35 g, 2.19 mmol), 
benzyltriethylammonium chloride (0.44 g, 1.95 mmol) and TMSCl (0.87 g, 8.06 
mmol) in DCM (~ 5 mL) and added to the reaction mixture. After several hours, 
TLC showed no starting material. The organic layer was washed with 0.1 M 
sodium thiosulfate and brine before being dried with magnesium sulfate. 
Evaporation of the solvent left a yellow solid (0.89 g) that had minor impurities 
by 1H NMR. A silica gel column was run with DCM to collect 14 (0.35 g, 32%) as 
a faintly yellow-white solid, mp 64–66 °C (chloroform-hexanes). 1H NMR (400 
MHz in CDCl3) δ 7.96 (d, 1H, J = 8.0 Hz), 7.74 (m, 2H), 7.56 (t, 1H, J = 7.6 Hz), 
6.10 (d, 1H, J = 10.4 Hz), 4.70 (d, 1H, J = 10.4 Hz) 3.89 (s, 3H). 
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(5-Iodo-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetic acid (15) and 
(7-Iodo-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetic acid (16): 
The electrophilic-iodine reagent was made by crushing iodine (185 mg, 0.73 
mmol) in 5 mL 98% sulfuric acid and addition of sodium iodate (153 mg, 0.77 
mmol), along with an additional 5 mL sulfuric acid (total moles of iodine, 2.23 
mmol). The electrophilic-iodine solution was allowed to stir for 30 min. 7 (400 
mg, 2.08 mmol) was dissolved in 5 mL of 98% sulfuric acid, and the 
electrophilic-iodine reagent was added dropwise over 20–25 min. The original 
reagent flask was rinsed with a small amount of sulfuric acid that was 
subsequently added to the reaction mixture, and the combined mixtures were 
allowed to stir for 3.5 h at rt. The reaction mixture was poured into an Erlenmeyer 
flask containing ice water (150 mL), and the reaction flask was rinsed with water 
(50 mL) that was subsequently added to the Erlenmeyer flask. The precipitate that 
formed was filtered and washed with water to yield 15 (210 mg, 32%) as an off-
white solid with a slight pink hue to it, mp 188–192 °C. The aqueous filtrate was 
extracted with EtOAc to yield about 300 mg of a crude, solid mixture. This was 
recrystallized with chloroform to yield an additional 55 mg of product with the 
same melting point as above. The remaining material was partially separated by 
silica gel cyclograph chromatography (2×) using 10–20% EtOAc in hexanes with 
< 2% acetic acid. The first band that eluted (~ 80 mg) was analyzed by 1H NMR, 
and the isolated material was identified as the ortho-substituted isomer 16 (~ 84% 
by NMR); < 30 mg of 15 was recovered from the cyclograph. 
15 1H NMR (500 MHz in acetone-d6 and TMS) δ 11.13 (br s, 1H), 8.16 (s, 1H), 
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8.12 (d, 1H, J = 8.1 Hz), 7.60 (d, 1H, J = 8.1 Hz), 5.89 (dd, 1H, J = 5.1, 7.3 Hz), 
3.16 (dd, 1H, J = 4.95, 17.0 Hz), 2.93 (dd, 1H, J = 7.5, 17.0 Hz). 
16 1H NMR (500 MHz in acetone-d6 and TMS) δ 11.11 (br s, 1H), 8.20 (d, 1H, J 
= 7.8 Hz), 7.88 (d, 1H, J = 7.6 Hz), 7.43 (t, 1H, J = 7.6 Hz), 5.78 (dd, 1H, J = 
2.3, 8.1 Hz), 3.54 (dd, 1H, J = 2.5, 17.0 Hz), 2.90 (dd, 1H, J = 8.2, 17.0 Hz). 
Ethyl (5-iodo-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (17): 
15 (698 mg, 2.19 mmol) was placed in a 50-mL RBF with 8 mL of MeCN. A brief 
reflux dissolved the solid prior to addition of cesium carbonate (1.71 g, 5.25 
mmol). Iodoethane (1.74 g, 11.1 mmol) was dissolved in 20 mL of MeCN and 
added to the salt mixture before the mixture was refluxed for 2 h. TLC in EtOAc 
and hexanes (1:2) showed two product spots forming, the higher of which was 
from opening of the lactone, causing the ethyl ester analogue of 1 to form. The 
reaction mixture was filtered to remove cesium salts, and the organic filtrate was 
evaporated. As much solid as would dissolve in 5 mL chloroform was collected, 
and the solution was washed successively with 5 mL of 5% aq NaHCO3 and brine 
prior to being dried with sodium sulfate. The solvent was evaporated to yield a 
viscous yellow oil (650 mg) as 17 with some diester impurity. This crude material 
was used without further purification to make 20. 1H NMR (400 MHz in CDCl3) δ 
8.24 (s, 1H), 7.99 (d, 1H, J = 8.0 Hz), 7.29 (d, 1H, J = 8.0 Hz, partial overlap 
with chloroform signal), 5.83 (app t, 1H, J = 6.4, 6.8 Hz), 4.21 (q, 2H, J = 7.2 
Hz), 2.95 (dd, 1H, J = 6.6, 16.6 Hz), 2.84 (dd, 1H, J = 6.4, 16.4 Hz), 1.27 (t, 3H, 
7.0 Hz). 
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Methyl (5-iodo-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (18): 
15 (270 mg, 0.85 mmol) and cesium carbonate (260 mg, 0.82 mmol) were stirred 
in a 2-mL RBF with 3 mL of MeCN, which turned to a milky white salt solution 
in ~ 3 min. Iodomethane (518 mg, 3.65 mmol) was dissolved in 2 mL MeCN and 
added to the reaction mixture. After stirring for 30 min at room temperature, the 
RBF was connected to a water condenser and gently heated (< 70 °C ). TLC after 
50 min of heating showed no more starting material, with a small amount of 1 
appearing as a higher spot. The MeCN was evaporated, and chloroform was 
added with subsequent filtration. The solid salt was dissolved in water and 
extracted with chloroform (3 × 20 mL). The organic extracts were combined with 
the filtrate and washed with brine before being dried with sodium sulfate. 
Rotoevaporation yielded a white oil (243 mg), and silica gel chromatography with 
30% EtOAc in hexanes isolated 18 (210 mg, 75%) from unreacted starting 
material. This material was immediately used to make 21. 
Ethyl (7-iodo-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (19): 
16 (500 mg, 1.57 mmol) and cesium carbonate (677 mg, 2.08 mmol) were stirred 
in MeCN (23 mL) at rt for 3 h. In that time, the initially yellow, sticky solid had 
broken apart into a cloudy, salt-like suspension. Ethyl iodide (1.07 g, 6.84 mmol) 
was dissolved in MeCN (2 mL) before being added to the reaction mixture, and 
the mixture was gently heated (< 65 °C) and stirred magnetically for 1 h. The stir 
bar stopped when the mixture became sticky and turned orange-yellow. The flask 
was removed from the heat source and stirred manually until the stir bar was 
freed. After an additional 1 h of stirring at rt, TLC showed no more reactant. A 
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similar work up used to isolate 18 was employed. A brown tinted solid was 
obtained upon solvent evaporation (350 mg, 64%). This material was 
contaminated by the diester that formed due to the lactone opening and by 
impurities in the starting material. 1H NMR (400 MHz in CDCl3) δ 8.06 (d, 1H, J 
= 7.7 Hz), 7.91 (d, 1H, J = 7.6 Hz), 7.31 (t, 1H, J = 7.7 Hz), 5.72 (dd, 1H, J = 2.8, 
8.4 Hz), 4.17 (q, 2H, J = 7.2 Hz), 3.52 (dd, 1H, J = 2.8, 16.6 Hz), 2.78 (dd, 1H, J 
= 8.4, 16.6 Hz), 1.24 (t, 3H, J = 7.1 Hz). 
5-iodo-2-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]benzoic acid (20): 
17 (350 mg, 1.01 mmol) and triethylamine (102 mg, 1.01 mmol) were stirred in a 
RBF in 5 mL MeCN at room temperature overnight. There was no change as 
judged by TLC. The volume of MeCN was reduced to 1 mL and more 
triethylamine (539 mg, 5.34 mmol) was added before the reaction mixture was 
gently heated (sand bath, ~ 60 °C). The reaction mixture was stirred until it was 
judged complete by TLC. EtOAc was added to the reaction material, and it was 
acidified with 3 M HCl (aq). The organic was removed and washed with brine 
before being dried with sodium sulfate. The organic solvent was rotary evaporated 
off. The residue was subjected to silica gel chromatography using EtOAc–hexanes 
(2:3) with < 2% AcOH to isolate 20 (280 mg, 80%) as an off-white solid 
contaminated with about 6% of the ethyl ester analogue of 22 by NMR. 1H NMR 
(400 MHz in acetone-d6) δ 8.47 (d, 1H, J = 16.0 Hz), 8.33 (s, 1H), 7.98 (d, 1H, J 
= 8.3 Hz), 7.61 (d, 1H, J = 8.3 Hz), 6.45 (d, 1H, J = 16.0 Hz), 4.21 (q, 2H, J = 
7.1 Hz), 1.29 (t, 3H, 7.1 Hz). 
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5-Iodo-2-[(1E)-3-methoxy-3-oxoprop-1-en-1-yl]benzoic acid (21): 
To 18 (210 mg, 0.63 mmol) was added triethylamine (130 mg, 1.29 mmol), which 
was stirred at rt before being gently heated in a warm water bath (~ 50 °C ). More 
triethylamine (120 mg, 1.19 mmol) was added before the reaction was judged 
complete by TLC. Addition of 3.5 mL of 1 M HCl (aq) was followed by 
chloroform extraction (3 × 2 mL). The organic layer was dried with sodium 
sulfate and evaporated to yield 200 mg of crude white solid which was 
recrystallized (CHCl3–hexanes) to yield 21 (105 mg, 50%) that was immediately 
used to make 24. 
3-Iodo-2-[(1E)-3-methoxy-3-oxoprop-1-en-1-yl]benzoic acid (22): 
The crude 19 (350 mg, 1.01 mmol) from an incomplete reaction with 
triethylamine was stirred in MeOH (5 mL) with NaOMe (50 mg, 0.93 mmol) for 1 
h at rt and monitored by TLC. The solution was heated by sand (45–75 °C) for 2 
nights (~ 40 h), and a 1H NMR spectrum of an aliquot showed the lactone opened 
with the ethyl ester replaced by a methyl ester (transesterification). Additional 
NaOMe (70 mg, 1.30 mmol) was added, and the reaction mixture heated until the 
reaction was complete by TLC. MeOH was evaporated before addition of water 
(10 mL), and the mixture was extracted with EtOAc (4 × 10 mL). The combined 
organics were washed with brine before being dried with sodium sulfate. 
Evaporation of the solvent yielded a solid (300 mg) that was recrystallized 
(DCM-hexanes) to give 22 (120 mg, 36%). 1H NMR (400 MHz in CDCl3) δ 10.72 
(br s, 1H), 8.11 (d, 1H, J = 7.9 Hz), 7.98 (d, 1H, J = 7.3 Hz), 7.92 (d, 1H, J = 16.2 
111 
Hz), 7.13 (d, 1H, J = 7.9 Hz), 5.99 (d, 1H, J = 16.2 Hz), 3.85 (s, 3H). Peaks 
corresponding to DCM and hexanes were present, too. 
2-(1,2-Dibromo-3-ethoxy-3-oxopropyl)-5-iodobenzoic acid (23): 
In 5 mL DCM were dissolved 20 (293 mg, 0.847 mmol) and bromine (140 mg, 
0.875 mmol). The reaction mixture was stirred at room temperature until the 
reaction was judged complete by TLC. The solvent and excess bromine were 
evaporated. The solid residue was redissolved in DCM prior to being washed with 
water and brine and dried with sodium sulfate to yield 350 mg of crude solid 
material. Repeated recrystallizations from DCM-hexanes yielded 23 (275 mg, 
64%) as a white solid, mp 162–165 °C. 1H NMR (500 MHz in CDCl3) δ 8.46 (s, 
1H), 7.99 (d, 1H, J = 8.5 Hz), 7.41 (d, 1H, J = 8.5 Hz), 6.83 (br s, 1H), 4.81 (br s, 
1H), 4.39 (q, 2H, J = 7.0 Hz), 1.39 (t, 3H, J = 7.0 Hz); Anal. Calcd (%) for 
C12H11Br2IO4: C, 28.49; H, 2.19. Found: C, 28.58; H, 2.15. 
2-(1,2-Dichloro-3-methoxy-3-oxopropyl)-5-iodobenzoic acid (24): 
Potassium permanganate (47.5 mg, 0.30 mmol) and benzyltriethylammonium 
chloride (69 mg, 0.30 mmol) were stirred in 2 mL of DCM for 20 min before 
addition of TMSCl (198 mg, 1.82 mmol) in 5 mL of DCM while on ice. To the 
reaction mixture was added 21 (95 mg, 0.29 mmol) with stirring. TLC of the 
reaction mixture showed product formation stopped without multiple spots having 
appeared (reactant/product degradation), but the green reaction mixture color had 
faded. A second equivalent of chlorinating reagent, as described above with 
KMnO4, benzyltriethylammonium chloride and TMSCl, was added, which 
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resulted in the starting alkene spot vanishing by TLC. Addition of 1 M sodium 
thiosulfate (aq) to quench the permanganate was followed by extraction of the 
organic layer with additional DCM. The combined organics were washed with 
brine before being dried by sodium sulfate. Purification by silica gel 
chromatography (EtOAc-hexanes) along with recrystallization 
(chloroform-hexanes) yielded 24 (61 mg, 52.9%) as a white solid, mp 159–162.5 
°C. 1H NMR (400 MHz in CDCl3) δ 8.47 (s, 1H), 8.00 (d, 1H, J = 8.4 Hz), 7.46 
(d, 1H, J = 8.4 Hz), 6.64 (d, 1H, J = 10.0 Hz), 4.68 (d, 1H, J = 10.0 Hz), 3.90 (s, 
3H). 
Methyl iodo(3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (25): 
Iodine (472 mg, 1.86 mmol), sodium iodate (194 mg, 0.98 mmol) and 98% 
sulfuric acid (8 mL) were combined and stirred for about 30 min. This solution 
was added to 1 and stirred at rt for 95 min. The reaction mixture was poured into 
ice water (60 mL) and extracted with EtOAc (3 × 40 mL). The combined organics 
were washed with brine and dried with sodium sulfate. Evaporation of the solvent 
yielded a crude off-white solid (1.26 g, 89%). Recrystallization from DCM and 
hexanes yielded 25 (1.12 g, 72%) as a white solid, mp 121.5–126.5 °C. This 
material was used in syntheses (26, 27, and 28) without extensive purification. 1H 
NMR (400 MHz, CDCl3): 7.94 (m, 2H), 7.72 (t, 1H, J = 7.6 Hz), 7.62 (t, 1H, 7.6 
Hz), 5.67 (d, 1H, J = 6.4 Hz), 4.79 (d, 1H, J = 6.0 Hz), 3.86 (s, 3H). 
Methyl iodo(5-iodo-3-oxo-1,3-dihydro-2-benzofuran-1-yl)acetate (26): 
Electrophilic-iodine reagent was prepared in a 50-mL RBF from iodine (480 mg, 
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1.89 mmol), sodium iodate (190 mg, 0.96 mmol) and 98% sulfuric acid (25 mL) 
with stirring for about 30 min. The dark red-black solution was added to 1 (940 
mg, 4.27 mmol). After being stirred for 1 h, the reaction mixture was poured into 
300 mL of cold water that was in an ice bath. The reaction flask was rinsed with 
50 mL of cold water that was added to the aqueous solution. Viscous black semi-
solid precipitated, and it was filtered after 1 h (the next day for some procedures) 
and rinsed with water. The black solid was dissolved in EtOAc that was washed 
with sodium bisulfite and brine prior to being dried with sodium sulfate and 
evaporated to provide a yellow oil. Additionally, the aqueous filtrate was 
extracted with EtOAc (3 × 300 mL), and washed and dried as above, to yield 
additional crude material. All the crude was subjected to another round of 
electrophilic-iodine reagent as described in the beginning of this procedure with 
similar workup steps. Silica gel chromatography (EtOAc-hexanes ) and 
recrystallization (CHCl3–hexanes) were used to isolate 26 (650 mg, 33% from 1) 
as a white solid, mp 134–135.5 °C. 1H NMR (500 MHz, CDCl3): δ 8.27 (s, 1H), 
8.02 (d, 1H, J = 8.0 Hz), 7.71 (d, 1H, J = 8.5 Hz), 5.57 (d, 1H, J = 5.5 Hz), 4.84 
(d, 1H, J = 6.0 Hz), 3.86 (s, 3H). 
Methyl (2Z)-(3-oxo-2-benzofuran-1(3H)-ylidene)ethanoate (27) and 
methyl (2E)-(3-oxo-2-benzofuran-1(3H)-ylidene)ethanoate (28): 
25 (115 mg, 0.35 mmol) was stirred in 0.5 mL of DCM with 180 mg triethylamine 
overnight. An additional 206 mg of triethylamine was added over the course of 
another day until the starting material spot disappeared by TLC (321 mg NEt3 
total, 3.18 mmol). The reaction mixture was acidified and extracted with EtOAc 
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to yield 90 mg of crude. Silica gel column chromatography with EtOAc-hexanes 
(7:3) was used to isolate 28 (15 mg, 21%) as the first material off the column and 
27 (12.5 mg, 17.5%) as the second material off the column. E-alkene, 28: 1H 
NMR (500 MHz, CDCl3): δ 9.06 (d, 1H, J = 8.0 Hz), 7.98 (d, 1H, d, J = 7.5 Hz), 
7.84 (t, 1H), 7.72 (t, 1H), 6.17 (s, 1H), 3.85 (s, 3H). Z-alkene, 27: 1H NMR (400 
MHz, CDCl3): δ 7.99 (d, 1H, J = 6.4 Hz), 7.78 (m, 2H), 7.70 (t, 1H), 5.90 (s, 1H), 
3.86 (s, 3H). 
Methyl (2E)-(5-iodo-3-oxo-2-benzofuran-1(3H)-ylidene)ethanoate (29) and 
methyl (2Z)-(5-iodo-3-oxo-2-benzofuran-1(3H)-ylidene)ethanoate (30): 
26 (140 mg, 0.31 mmol) was treated with distilled and dried triethylamine (75 mg, 
0.74 mmol) in < 0.5 mL of CHCl3 in a conical vial. The reaction mixture turned 
yellow immediately, and some solid precipitated. An air condenser and drying 
tube were attached, and the reaction mixture warmed to about 45 °C on a sand 
bath. After 2 h, TLC showed starting material still present. Additional 
triethylamine (65 mg, 0.64 mmol) was added, and the reaction mixture was stirred 
at ~ 45 °C overnight. The next day, chloroform and 1 M HCl (aq) were added to 
the now red reaction solution, which faded to a clear yellow color once stirred. 
The solution was extracted with CHCl3 (3 × 4 mL), the organics combined and 
washed with brine before drying with sodium sulfate to yield 93 mg of crude 
yellow oil. The aqueous was also extracted with EtOAc (2 × 8 mL), which was 
similarly washed and dried to yield 93 mg of yellow solid. The two extracted 
materials were combined and subjected to column chromatography with EtOAc 
and hexanes, and 29 eluted first. A white solid was obtained upon recrystallization 
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with DCM and hexanes (60 mg, 60%), mp 170.5–172.5 °C. A small amount of the 
Z-isomer 30 was isolated but slightly impure (20 mg, <20%). 29: 1H NMR (500 
MHz, CDCl3): δ 8.81 (d, 1H, J = 8.5 Hz), 8.31 (s, 1H), 8.13 (d, 1H, J = 8.0 Hz), 
6.19 (s, 1H), 3.85 (s, 3H). 
30: 1H NMR (500 MHz, acetone-d6): δ 8.37 (s, 1H), 8.28 (d, 1H, J = 8.0 Hz), 
7.96 (d, 1H, J = 8.0 Hz), 6.22 (s, 1H), 3.81 (s, 3H). 
3-(Nitromethyl)-2-benzofuran-1(3H)-one, “3-nitromethylphthalide,” (31): 
Nitromethane (4.27 g, 66.5 mmol) and 2-formylbenzoic acid (10 g, 66.7 mmol) 
were stirred in a 250-mL RBF with MeOH (40 mL) while on an ice-water bath. 
Sodium hydroxide (6.43 g, 156 mmol), dissolved in water (22 mL), was cooled on 
ice then added to the RBF. After 80 min of being stirred on ice, 40 mL of 5 N HCl 
(aq) was added to the stirred solution. A few color changes occurred but faded 
quickly before the solution became pale yellow and then colorless. In about 5 
min, a white precipitate developed. The solution was stirred 4.5 h (or overnight in 
some procedures) on a fresh ice bath before filtration. The filtered solid was 
washed with about 150 mL water and dried on a vacuum filter. Additional drying 
on dry filter paper and vacuum-oven drying yielded 31 (12.0 g, 93%) as a white 
solid, mp 129.5–131.5 °C that could be optionally recrystallized (MeOH) to yield 
colorless blocks with a similar melting point. 
1H NMR (400 MHz, acetone-d6): δ 7.89 (d, 2H, J = 7.7 Hz), 7.84 (d, 2H, J = 4.3 
Hz), 7.69 (m, 1H), 6.29 (dd, 1H, J = 2.9, 8.3 Hz), 5.44 (dd, 1H, J = 2.8, 14.5 Hz), 
4.98 (dd, 1H, J = 8.4, 14.5 Hz). 
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6-Iodo-3-(nitromethyl)-2-benzofuran-1(3H)-one (32): 
Iodine (6.23 g, 24.5 mmol) was partially crushed in 113 mL of 98% sulfuric acid. 
Sodium iodate (2.45 g, 12.4 mmol) was added with an additional 40 mL of 98% 
sulfuric acid. The electrophilic-iodine reagent was stirred 40 min before the 
solution turned a dark, brown-red color. 31 (9.64 g, 49.9 mmol) was added to the 
solution and stirred 140 min before the reaction mixture was poured into 1000 g 
of ice. The reaction flask was rinsed with water that was also poured into the same 
ice flask. The flask was placed in an ice bath and stirred overnight. The solution 
was vacuum filtered and washed with more water before the filtered solid was 
dissolved in EtOAc (150 mL). The organic solution was washed with saturated 
sodium bisulfite (turning the solution from dark red to orange-yellow) and brine 
before being dried with sodium sulfate. About 12.5 g of sticky, yellow solid was 
recovered after evaporation of the EtOAc. About 40 mL of DCM was added to the 
crude material and everything dissolved except 4.1 g of pink-yellow solid. The 
solid was filtered and collected, and the DCM filtrate was placed in the freezer 
overnight to precipitate additional solid. The initially insoluble solid (4.1 g) and 
precipitate from overnight freezing, which was collected by filtration, totaled 5.5–
6 g. Recrystallization yielded 32 (4.6 g, 28.8%), as a white solid (CHCl3) or white 
needles (EtOH), mp 126–129 °C for both. 1H NMR (400 MHz, acetone-d6) δ 8.23 
ppm (s, 1H), 8.20 ppm (d, 1H, J = 8.0 Hz), 7.70 ppm (d, 1H, J = 8.0 Hz), 6.30 
ppm (dd, 1H, J = 3.2, 8.2 Hz), 5.44 ppm (dd, 1H, J = 2.8, 14.8 Hz), 5.04 ppm (dd, 
1H, J = 8.2, 14.7 Hz). 1H NMR (400 MHz, CDCl3 and TMS) δ 8.31 ppm (s, 1H), 
8.06 ppm (d, 1H, J = 8.0 Hz), 7.30 ppm (d, 1H, J = 8.0 Hz), 6.08 ppm (dd, 1H, J 
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= 4.6, 7.4 Hz), 4.81 ppm (dd, 1H, J = 4.5, 14.1 Hz), 4.73 ppm (dd, 1H, J = 7.5, 
14.1 Hz).  
3-[Dibromo(nitro)methyl]-2-benzofuran-1(3H) (33): 
31 (1.922 g, 9.96 mmol) was dissolved in DCM (5 mL). NaHCO3 (919 mg, 10.9 
mmol) dissolved in water (10 mL) was added to the organic phase and stirred 
vigorously while on an ice-water bath. Bromine (1.6 g, 10.0 mmol) was dissolved 
in 5 mL DCM and added to the biphasic mixture. The reaction was stirred on ice 
for 2.5 h before the reaction material was allowed to warm to rt. Optionally added 
was sodium bromide (200 mg, 1.94 mmol; for some reactions). After the red color 
faded (~ 5 h), a second equivalent of bromine (1.6 g, 10 mmol) dissolved in DCM 
(5 mL) was added. The reaction mixture was placed back on ice before addition of 
the second equivalent of NaHCO3 (0.870 g, 10.4 mmol) with 3 mL of water. The 
reaction mixture was again warmed to room temperature and stirred until the 
reaction mixture was complete by TLC (48–72 h). The organic solution was 
extracted before being washed with brine and dried with sodium sulfate. 
Rotoevaporation yielded 33 (2.68g, 76.7%) as a white solid (mp 95–99 °C) and 
colorless blocks upon recrystallization, mp 98.5–101.5 °C (EtOAc-hexanes). 1H 
NMR (400 MHz, CDCl3 and TMS) δ 8.00 ppm (d, 1H, J = 7.6 Hz), 7.88 ppm (d, 
1H, J = 7.8 Hz), 7.81 ppm (t, 1H, J = 7.4, 7.6 Hz), 7.73 ppm (t, 1H, J = 7.5 Hz), 
6.40 ppm (s, 1H). 
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3-[Bromo(nitro)methyl]-2-benzofuran-1(3H)-one (34): 
32 (1.187 g, 3.72 mmol) was stirred in chloroform (5 mL) on an ice bath. 
Pyridiniumbromide perbromide (2.69 g, 7.57 mmol) was added as a solid, and 
2,6-lutidine (841 mg, 7.86 mmol) was dissolved in chloroform (5 mL) before 
being added one molar equivalent at a time. The second equivalent of each was 
added after the red solution color faded to orange (< 3 h). The flask was allowed 
to warm to about 15 °C until the reaction was complete by TLC (~ 7 h). The 
organic solution was washed with 1 M HCl (3 × 25 mL) and brine before being 
dried with sodium sulfate. Evaporation of the organic yielded a yellow solid after 
vacuum drying (1.46 g). Silica gel chromatography with DCM yielded a yellow 
solid, too (1.3 g). Recrystallization provided 34 (0.880 g, 49.7%) as a white 
powder, mp 117–122 °C (EtOAc-hexanes). White needles (120 mg) were 
recovered from the mother liquor, and the residual crude from evaporation of the 
mother liquor was recrystallized again to yield a lightly yellowed solid (162 mg) 
and light needles (130 mg), mp 117–122 °C. 1H NMR (400 MHz, CDCl3 and 
TMS) δ 8.32 ppm (s, 1H), 8.12 ppm (d, 1H, J = 8.4 Hz), 7.66 ppm (d, 1H, J = 8.0 
Hz), 6.36 ppm (s, 1H). 13C NMR (100 MHz) δ 165.7, 143.7, 142.7, 135.4, 128.9, 
125.4, 97.2, 87.2, 83.1 ppm. 
(R*, S*)-3-[Bromo(nitro)methyl]-2-benzofuran-1(3H)-one (35): 
33 (1.792 g, 5.11 mmol) was dissolved in AcOH (10.5 mL). Thiourea (0.390 g, 
5.12 mmol) was dissolved in water (11 mL) and added dropwise over 4–5 min to 
the AcOH solution while being magnetically stirred. As the aqueous thiourea 
solution was added, the reaction mixture turned yellow, and precipitate 
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continually developed after half of the aqueous-thiourea solution was added. The 
reaction mixture was vacuum filtered 40 min after the initial aqueous solution 
addition, and the solid was washed with about 100 mL of water. The light yellow 
crude material (1.067 g, 76.8%) was dried on vacuum filter. Additional precipitate 
formed in the filtrate and was collected (0.100 g orange-yellow solid). The 
original precipitate was recrystallized with EtOAc and hexanes to yield 35 (0.660 
g, 47.5 %) as white needles, mp 127–129.5 °C (~ 45:1 diastereomer ratio of 35:36 
by NMR comparison of the doublets between δ 6.4 and 6.0 ppm; presumably 
reacemic). 1H NMR (400 MHz, CDCl3 and TMS) δ 7.99 ppm (d, 1H, 7.6 Hz), 
7.79 ppm (t, 1H, J = 7.6 Hz), 7.69 ppm (t, 1H, J = 7.6 Hz), 7.60 ppm (d, 1H, J = 
7.6 Hz), 6.36 ppm (d, 1H, J = 4.0 Hz), 6.19 ppm (d, 1H, J = 3.6 Hz); 13C NMR 
(100 MHz) δ 168.1, 143.1, 135.1, 131.1, 126.6, 126.3, 122.5, 80.5, and 78.7 ppm; 
Anal. Calcd (%) for C9H6BrNO4: C 39.73, H 2.22, N 5.15. Found: C 39.66, H 
2.24, N 5.11. 
(R*, R*)-3-[Bromo(nitro)methyl]-6-iodo-2-benzofuran-1(3H)-one (37): 
34 (153 mg, 0.32 mmol) was dissolved in 0.5 mL THF and stirred in an ice bath. 
Thiourea (52 mg, 0.68 mmol) was dissolved in 0.3 mL THF and 0.7 mL 1 M HCl 
and cooled on ice prior to being added. The thiourea solution was added dropwise 
over about 3.5 min, however the rate of addition was later determined to not be 
important. The lower layer was immediately removed, and the aqueous was 
extracted with DCM. The THF layer and DCM extract were combined and 
evaporated. The residue was taken up in DCM, which was washed with 1 M HCl 
(aq) and brine before being dried with sodium sulfate. Evaporation of the organic 
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left a faintly tan oil (116 mg). Several recrystallizations from EtOAc and hexanes 
yielded 37 (26 mg, 20%) as colorless blocks of one diastereomer (presumably 
racemic) by 1H NMR, mp 107–110 °C. 1H NMR (400 MHz, CDCl3 and TMS) δ 
8.31 ppm (s, 1H), 8.09 ppm (d, 1H, J = 8.0 Hz), 7.35 (d, 1H, J = 8.0 Hz), 6.33 
ppm (d, 1H, J = 3.6 Hz), 6.10 ppm (d, 1H, J = 3.6 Hz);  13C NMR (100 MHz) δ = 
166.2, 143.8, 142.4, 135.6, 128.3, 124.0, 95.5, 79.7, and 78.7 ppm; Anal. Calcd 
(%) for C9H5BrINO4: C 27.16, H 1.27, N 3.52. Found C 27.29, H 1.12, N 3.54. 
 
Table 8. Reduction of 34 by Thiourea in Various Systems 
Compositiona Thiourea, HClb 
Diastereomer Doublets 
(3.6 Hz, 7.2 Hz)
c
 
THF, H2O (5:1) 0.99
d
 3, 1 
THF, AcOH (1:1) 1 2, 1e 
THF, HCl (3:1) 1, ~ 3 ~ 3, 1 
THF, H2O (1:2) 2.13
d
 ~ 1.28, 1 
THF, HCl (3:1) 2, 0.19 ~ 2.4, 1 
THF, HCl (2.2:1)f 1, 1 ~ 5, 1 
THF, NaHCO3 
(2:1)g 
~ 1, 1g ~ 2.25, 1 
a Ratio displayed is by volume. 
b In molar equivalents for each substance in comparison to 34. 
c Doublet ratio is from crude 1H NMR, with 3.6 Hz attributed to 34 and 7.2 Hz the 
unisolated diastereomer (R*, S*). 
d Only thiourea was used and no acid. 
e About 25% of the material remaining is 34, by 1H NMR. 
f Experimental for this reaction is described above. 
g Sodium bicarbonate used in place of HCl. 
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SRB Assay105 
Inhibition of human cancer cell line growth was performed by Dr J. C. Chapuis 
and determined using the NCI’s sulforhodamine B assay as previously described. 
In summary, cells in a 5% fetal bovine serum/RPMI 1640 medium were 
inoculated in 96-well plates and incubated for 24 h. The compounds were added 
as serial dilutions. After 48 h, the plates were fixed with trichloroacetic acid, 
stained with sulforhodamine B and read with an automated microplate reader. 
Growth inhibition data (GI50 and TGI) and cell death data (LC50) were calculated 
from optical density with Immunosoft software. 
MTT Assay106 
Inhibition of human cancer cell line growth was performed by Dr J. C. Chapuis. 
Cells were treated with a range of concentrations of each compound and seeded in 
96-well plates with 200 µL/well and five wells per sample concentration at a 
density of between 1–4 × 104 cells/mL. Control cells were treated with 0.1% 
DMSO and blank wells were loaded with medium only. After 5 days, 50 µL 1.0 
mg/ml MTT was added to each well and the plates were incubated for 4 h at 37 
°C prior to dissolution of fomazan crystals in 200 µL DMSO. Absorbance at 570 
nm was determined for each well, and the survival fraction for each was 
calculated from the following ratio: (mean A570 treated cells – mean A570 blank 
wells) / (mean A570 control – mean A570 blank). The IC50 was determined using 
CalcuSyn software (Biosoft, Cambridge, UK). 
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Synthesis of bromonitromethane from nitromethane (essentially as described by 
Slagh72): 
Water (120 mL) was added to an Erlenmeyer flask and cooled on ice prior to 
addition of NaOH pellets (4.178 g, 101.3 mmol). After the solid dissolved, 
nitromethane (6.510 g, 101.3 mmol), previously cooled on ice, was poured into 
the aqueous solution. The mixture was swirled for 1 min and immediately poured 
into a 500 mL RBF that was placed in a salt-ice bath with a stir bar and bromine 
(16.32 g, 101.5 mmol). Initially, the mixture was swirled vigorously by hand, and 
then it was stirred magnetically for 25 min. The red bromine color faded and a 
yellow-white oil developed. The mixture was distilled to collect the products and 
water in a Dean-Stark trap. Upon cooling, the products separated from water as 
the lower layer and were transfered to a vial prior to being stored in a freezer (-20 
°C) overnight. Small water droplets appear, and the organic is removed to a new 
vial and stored overnight. Droplets did not form again. 1H NMR (400 MHz, 
CDCl3 and TMS) δ 7.22 (s, 1.00, 4.73%, CHBr2NO2), 5.72 (s, 36.32, 85.59%, 
CH2BrNO2) and 4.33 (s, 5.91, 9.32%, CH3NO2).  
Table 9. Composition of Brominated Nitromethane by 1H NMR 
Substance 
Proton Integration 
value (I.V.) 
I.V. / total # of 
protons 
% Compounda 
CH3NO2 5.91 1.97 9.32 
CH2BrNO2 36.3 18.2 85.6 
CHBr2NO2 1.00 1.00 4.73 
a 100% × (integration value ÷ total # of protons) ÷ (1.97 + 18.16 + 1.00) 
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Crude product in Chapter 2.9, 2-formylbenzoic acid reaction with 
bromonitromethane to produce 7.5 Hz doublets attributed to 
(R*, R*)-3-[bromo(nitro)methyl]-2-benzofuran-1(3H)-one (36): 
2-Formylbenzoic acid (150 mg, 1 mmol) and sodium bicarbonate (86 mg, 1 
mmol) were dissolved in water and EtOH (1 mL each) in a 25 mL RBF that was 
placed on an ice-water bath. Methylamine (40% in water, 8 mg, 0.1 mmol) and 
sodium carbonate (15 mg, 0.15 mmol) were added to the RBF and stirred 
magnetically. Bromonitromethane (490 mg, < 3.5 mmol) was dissolved in EtOH 
(5 mL) and added over 65 min to the stirred solution. The solution was faintly red 
by complete addition and stirring was continued. After an additional 2.5 h, water 
(15 mL) and 10% H2SO4 (3 mL) were added, and the acidic solution was stirred 
overnight at rt. The faintly yellow precipitate was collected by filtration and dried; 
mp (116–119 °C) and 1H NMR (Major:Minor, i.e., 36:BNLA product, ~ 6.6:1). 1H 
NMR (400 MHz, CDCl3 and TMS) δ 7.99 (d, 1H, J = 7.7 Hz), 7.78 (m, 2H), 7.70 
(m, 1H), 6.13 (d, 1H, J = 7.5Hz), 6.02 (d, 1H, J = 7.5Hz).  
Minor product: δ 8.41 (d, 1H, J = 7.9 Hz), 7.92 (m, 2H), everything else was 
overlapped by the major product, suspected 36. 
PTP assay with DIFMUP (for 24, 29, 33, 35 and 37): 
Compounds were prepared as 5 mM DMSO stock solutions except for 29, which 
was prepared as a 2.5 mM solution after UV solubility results (see page 134). 
They were diluted 2 µL into a total volume of 100 µL of appropriate buffer 
(correspondence with Millipore, Ltd.) with 0.1 mM DTT at pH 7.2 containing 
individual PTP enzymes (CD45, PTP1B, SHP1, SHP2 and TCPTP). The 
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fluorescence measurement obtained by hydrolysis of the substrate from wells with 
a compound were compared to control wells without the compound to which 2 µL 
of DMSO was added, to determine the activity of each enzyme. This assay was 
conducted by Millipore Corporation under their Enzyme Profiling Services, and 
the assay results were released on March 13, 2012 (QA Report: George, Charles; 
QC Report: Jackson, Wayne). 
Assay, pNPP (2–5, 14, 23, 24, 27, 28 and 29) 
Original buffer stock solution: 
 1 mM EDTA, 0.5 mM 3,3-dimethylglutaric acid, 0.15 M NaCl, and 0.01% 
Triton X-100 was prepared at pH 7 for the stock buffer. The assay buffer 
contained 1–10 mM DTT added to the stock buffer. The pNPP substrate was 
prepared from pellets purchased from Sigma Aldrich and dissolved in the stock 
buffer. The final pNPP concentration in the enzyme assay was typically 10 mM. 
 PTPβ was purchased from U.S. Biological as the E. coli expressed 
catalytic domain (a.a. 1675–1996) that was 90% by SDS-PAGE with a specific 
activity of 40 U/µg. Manufacture’s definition, “One unit will hydrolyze 1 nmole 
of pNPP per minute at pH 7.4 and 30 °C.” It was supplied as 20 µg (800 units) in 
25 mM Tris-HCl, pH 8.0, 75 mM NaCl, 0.05% Tween-20, 50% glycerol, 2 mM 
EDTA, 3 mM DTT and 10 mM glutathione. This was diluted with stock buffer to 
slightly more than twice the original volume and separated into nine aliquots. 
Eight of the aliquots, 4 µL, were estimated to contain 94 units each, and the last 
vial, ~ 2 µL, had 47 units. These aliquots were stored at -70 °C and diluted with 
additional stock buffer prior to use in assays. 
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 PTP1B was purchased from U.S. Biological as the E. coli expressed 
catalytic domain (a.a. 1–321) that was 95% by SDS-PAGE with a specific 
acitivity of 6,000–12,000 units/mg. Manufacture’s definition, “One unit will 
hydrolyze 1 nmole of pNPP per minute at pH 7.4, 37 °C using 10 mM substrate.” 
It was supplied as 250 µg (1500–3000 units) in 25 mM Tris-HCl, pH 7.5, 2 mM 
β-mercaptoethanol, 1 mM EDTA, 1 mM DTT and 20% glycerol. Stock buffer was 
added to nearly double the volume, and eleven aliquots were made from this 
dilution. Ten aliquots had about 23 µg (138–376 units) and the final one had 18.5 
µg (111–222 units). These aliquots were stored at -70 °C and diluted with 
additional buffer prior to use in assays. 
Enzyme assays used stock buffer with added DTT (1–10 mM). The 
enzyme aliquots were diluted to 250 µL with the DTT buffer, and 5 µL of the 
enzyme in buffer was used per well (PTPβ ~ 1.88 units & PTP1B ~ 2.31 µg, 13–
27 units). Potential inhibitors were dissolved in DMSO solutions to a final 
concentration of 40–73 mM. An inhibition assay was attempted by dilution of the 
DMSO stocks into assay buffer with enzymes for a few of the compounds, but not 
all appeared to remain soluble. The DMSO-stock of each compound was then 
diluted into stock buffer to achieve soluble concentrations of 0.12–1.06 mM. 
These solutions were stored in the dark at about 4 °C overnight and allowed to 
warm to room temperature without precipitate forming, before being used. These 
pre-diluted mixtures were used in the assays in varying amounts, usually between 
10–20 µL, to obtain final assay concentrations between 50–120 µM. 
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The inhibition of the enzymes was monitored by addition of the compound 
solutions or stock solution (blank) to the enzyme. After incubation for 10–60 min, 
pNPP was added. After 1–3 min, 1 M NaOH (aq) was added to stop the reaction, 
and the absorbance at 405 nm was measured. Regardless of the compound used or 
its concentration, there was never a consistently measurable difference between 
the wells with compounds and the control. 
UV experimental: 
Solubility determination for 24, 29, 33, 35 and 37 prior to submission for 
DIFMUP assay107 
 A 5 mM DMSO stock solution was made for each compound. The 
experiment was conducted in duplicate, with DMSO stock solutions diluted 2 µL 
of 5 mM of compound into 98 µL of phosphate-buffered saline (PBS), pH 7.4 
(purchased from Sigma) to acquire 100 µM concentration of compound. Blank 
wells were included by dilution of 2 µL of DMSO into 98 µL of PBS. Absorbance 
readings were taken at 630 nm at room temperature initially and then at the 
planned DIFMUP-PTP assay temperature of 37 °C. The absorbance value for 
every compound except 29 was below or between the absorbance readings for the 
two blank wells when at room temperature. The absorbance value for every 
compound well was below the blank readings upon warming to 37 °C except for 
the wells with 29 in them. They still returned absorbance values up to five times 
greater than the blank readings. Reducing the concentration of 29 by half (by 
addition of 1 µL of 5 mM 29 and 1 µL of DMSO to 98 µL of PBS) and 
reacquisition of the absorbance resulted in values below the blank absorbance 
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values. 
 33, 35 and 37 were again made into 5 mM DMSO stock solutions. For 
PBS spectra, 2 µL of the DMSO stock was diluted to 100 µL in a Costar UV plate 
with PBS, pH 7. The spectra were acquired from 200–400 nm. Glass-distilled 
water, pH 7, was used for the water spectra, and they were collected at 100 µL 
volumes similar to PBS spectra. For the figure with spectra titled as having 50 µL 
of 2 M NaOH (aq) added (Figure 39), the final volume was 150 µL. Blank spectra 
were acquired with DMSO in place of the DMSO-inhibitor stock solution and 
addition of the same amount of 2 M NaOH (aq). Absorbance values of blank 
wells were subtracted from experimental wells, and molar absorptivity was 
determined as described below. 
Molar absorptivity (ε, M-1cm-1) is calculated from the Beer’s Law (eqn1).  
1. A = εcℓ 
The absorbance (A) is found as optical density, and the concentration (c) is known 
from the inhibitor preparation. The path length (ℓ) was calculated from the 
dimensions of the wells of the plate as provided by Corning, the manufacturer of 
Costar plates.108 Well dimensions of Costar UV plate are as follows:  
Well depth = 10.67 mm; diameter (top; bottom) = 6.86 mm; 6.35 mm; Well 
Volume = 360 µL. Since the well diameter varies, the calculation is an 
approximation, but the volume is similar to a cylinder (eqn 2): 
2.   
 
V cylinder =
πh D2
4
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The beam passes through a length of solution equal to the height of the cylinder 
(eqn 3): 
3.   
The diameter at the top of the solution depends on the final volume, and it must 
be between the maximum and minimum diameter. If VF is the final volume of the 
solution, then Dʹ will be the new diameter at the top of the solution with that 
volume (eqn 4): 
4.    
If the final volume in equation 4 is the same as the maximum well volume (360 
µL), then Dʹ will be equal to Dtop because ∆D + Dbottom = Dtop. Replacing D in 
equation 3 with Dʹ from equation 4 provides the height (h). Taking VF as 100 µL, 
affords Dʹ as 6.492 mm and height as 3.02 mm (or 0.302 cm) as the path length 
traveled. This calculation was used to find ℓ in equation 1 that afforded values for 
molar absorptivity, ε. It should be noted that simpler calculations have been used 
to determine ℓ, in which the height is determined using equation 3 with the lower 
well diameter being used for D.109 
 
Description of reactions with 35 found in Table 7. 
For the reaction mixture with pyridine only: 
Mercaptoethanesulfonate sodium salt, MESNA, and pyridine, which was 
h =
4Vcylinder
πD2
D ' = (
V F
360 μ L) ΔD + Dbottom
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previously distilled from CaO and stored over 3 Å Molecular Sieves, were added 
to a 5 mL conical vial and magnetically stirred in an ice-water bath. Solid was still 
present after stirring for 30 min. After 35 was added to the vial, all solids 
appeared to be more soluble with a distinct yellowing of the liquid. Within 10 
min, the solution was orange. After warming to 16 °C over 2 h, the reaction 
mixture was acidified with 1% aq H2SO4 and extracted with DCM. The organic 
phase was washed with brine and dried with sodium sulfate before the solvent 
was evaporated to yield a dark yellow solid. A 1H NMR spectrum of the crude 
material matched 31 with minor impurities. 
For every other reaction in Table 7: 
35 was added to PBS, followed by addition of the indicated thiol (for the two-
phase system, 35 was first dissolved in DCM, then PBS was added and MESNA, 
previously dissolved in PBS, was added last). For aqueous-only reactions, 35 was 
not entirely soluble. The reaction mixture was stirred for at least 24 h (24–32 h), 
and the amount of precipitate noticeably increased over that time. The solid was 
collected by vacuum filtration, and a 1H NMR spectrum of the material was 
collected. 
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5. FUTURE WORK 
 
 Protein tyrosine phosphatase assays would need to be continued for the 
bromo nitro lactones 33, 34, 35 and 37. The single concentration inhibitor assay 
with DIFMUP supports PTPs as a potential target during cancer cell inhibition. 
However, detailed inhibition kinetics for these inhibitors are still in their infancy. 
 There are a number of issues that would need to be addressed during these 
investigations, though. The catalytic cysteine requires a reducing agent, usually in 
the form of DTT, to generate the reactive thiolate. Oxidation of cysteine by 
hydrogen peroxide in vivo is believed to be a control mechanism utilized by 
cells.
109
 Excess DTT is needed to reduce any sulfenic acid or intramolecular 
disulfide bonds (Figure 48). 
 
Figure 48. Cysteine-enzyme oxidation by hydrogen peroxide and reduction by 
thiol (from Denu and Tanner
110
). 
Excessive oxidation of the cysteine can lead to formation of a sulfonic acid, which 
is not reduced by DTT back to the active thiolate (Figure 49). PTPs can protect 
the cysteine thiol by forming an intramolecular sulfenamide with a nitrogen on the 
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backbone. However, this protective mechanism does not last in high peroxide 
concentration (Figure 49). 
 
Figure 49. Cyclic sulfenamide formation upon cysteine oxidation; see 
Blaskovich.
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 Oxidation of the cysteine has led to incorrectly labeling compounds as 
irreversible alkylating inhibitors when they were inhibiting by oxidization of the 
cysteine. Unusual inhibition kinetics have been observed, and in some cases, the 
only variation from one assay to another was the concentration of DTT 
(Blaskovich;
95
 specifically see reference 448 and 489 cited within). In general, 
reactive oxygen species (ROS) are generated in the form of peroxides that oxidize 
the cysteine to a sulfenic or a sulfonic acid. Furthermore, inhibitors that function 
via oxidation of the cysteine will not selectively inhibit a single PTP but the entire 
family will be targeted. False hits brought on by peroxide-induced oxidation can 
be examined during the assay by including antioxidant enzymes like catalase or 
superoxide.
111
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 Inhibition kinetic studies would need to follow if the inhibitors are not 
acting as oxidizing agents. The rate of irreversible inhibition can be checked 
during enzyme assays.
112
 Briefly, an aliquot of the pre-incubated enzyme-
inhibitor is removed at various time points, and the enzyme activity is measured 
and compared to control, i.e. enzyme-only aliquot. Reversible inhibitors are more 
likely to disassociate from the enzyme when aliquots are taken, and enzyme 
activity would be expected to recover partially or completely. 
 Additional investigation by HSQC can be done as described in Chapter 
1.4, regardless of the irreversible or reversible nature of inhibition. HSQC 
experiments done by Pei and colleagues
48, 50
 were used to propose a slow-binding 
reversible inhibition profile for peptidyl nitrostyrenes. The inhibitors would need 
to be synthesized from 
13
C enriched nitromethane, however. 
 There was some evidence to suggest 33 is able to form a bromo nitro 
lactone alkene (BNLA). A more basic solution possibly generated an analogue of 
phthalic acid. By extension, 34 can likely generate similar products. The BNLA 
analogue is believed to be the inhibitory compound for 33, and not the phthalate 
analogue. Phthalic acids have been investigated previously for any toxic potential 
since phthalate esters are commonly used plasticizers. Phthalic acid is not toxic 
and readily excreted when given to mice.
113, 114
 Therefore, it is not expected to be 
inhibiting cell growth or the PTPs. An enzyme assay using phthalic acid can be 
done at the same time as the bromo nitro lactones for additional confirmation, 
however. 
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6 CONCLUSION 
 The modification of the oxalylamino group that incorporated halogens was 
intended to irreversibly bind to the catalytic cysteine of PTPs. Some cinnamic 
acid analogues inhibited cancer-cell growth, but none of them were able to inhibit 
PTP1B or PTPβ in an assay with pNPP as substrate. The most effective cinnamic 
acid analogues at inhibiting cancer-cell growth, 24 and 29, were also analyzed in 
an assay with PTP1B and four different PTPs using DIFMUP as a substrate 
(Table 6). Enzyme activity for PTP1B was unaffected at 100 µM (23) and 50 µM 
(29) concentration of inhibitor. The same result was obtained for three of the four 
other PTPs. Enzyme activity for SHP-2 was slightly reduced by these two 
compounds, however. 
 The replacement of carboxyl group on the propenoate substituent with a 
nitro group along with bromine substitution led to inhibition of cancer-cell growth 
and cancer cell death. Additionally, all the PTPs were found to be inhibited in the 
same DIFMUP assay that the cinnamic acid analogues were not active in. A 
bromo nitro alkene may be formed in buffer by these compounds (33, 34, 35 and 
37). UV experiments with 33 indicate a possible bromo nitro lactone alkene 
forming in buffer, and it may be the compound responsible for inhibition. 
Confirmation of 35’s ability to undergo lactone ring opening and form a 
bromonitrostyrene intermediate was not as convincing. The UV experiments 
indicated a slowly emerging peak around 340 nm after 19 h in PBS that may have 
been from the conjugated bromonitrostyrene. However, this intermediate could 
134 
not be confirmed, as only reduction from 35 to 31 seemed to be occurring with 
thiols. 
 Nitrostyrenes have been investigated for their ability to alkylate 
nucleophiles and inhibit cancer cell growth and protein tyrosine phosphatases. 
The brominated nitro lactone compounds will need to be studied further to 
identify their mode of inhibition and to determine if they can be modified to 
selectively target specific PTPs or other relevant targets. 
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